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Abstract 
The chlamydiae are obligate intracellular parasites that have evolved specific 
interactions with their various hosts and host cell types to ensure their successful 
survival and consequential pathogenesis. The species Chlamydia pneumoniae is 
ubiquitous, with serological studies showing that most humans are infected at some 
stage in their lifetime. While most human infections are asymptomatic, C. 
pneumoniae can cause more severe respiratory disease and pneumonia and has been 
linked to chronic diseases such as asthma, atherosclerosis and even Alzheimer’s. The 
widely dispersed animal adapted C. pneumoniae strains cause an equally wide range 
of diseases in their hosts. Despite extensive information on the genetic diversity of 
human and animal C. pneumoniae isolates, knowledge concerning the cellular 
mechanisms of C. pneumoniae infections between human and animal hosts is 
presently unknown. To address this gap in the literature, the present study (1) 
provides a detailed characterisation of human and animal C. pneumoniae isolates 
response to an essential host antichlamydial effector interferon gamma (IFN-γ) and 
shows that the human C. pneumoniae isolates are more sensitive to tryptophan 
limitation and respond by rapidly reverting to persistent phase, and (2) further 
examines human and animal C. pneumoniae specific response to antibiotic (penicillin 
G) and identifies that only the human isolates alters its developmental cycle to 
survive penicillin G treatment. In contrast, the animal isolates do not appear to be 
able to adapt and form persistent forms as effectively as the human isolates. Not only 
was there less evidence of persistent morphologies and reduced growth, but these 
reductions in growth were not able to be fully rescued by changing the culture 
conditions, suggesting that either death or failure to infect (or both), rather than 
persistence alone, is likely to account for at least some of the loss of infectious yield 
in the presence of IFN-γ or penicillin treatment for these animal strains. Thus, the 
findings of this study support the possibility of entering into persistent as a positive 
survival mechanism by human C. pneumoniae isolates and may reflect the chronic 
nature of infections in humans.  
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 16Chapter 1: Introduction 
1.1 A DESCRIPTION OF THE SCIENTIFIC PROBLEM INVESTIGATED  
 
C. pneumoniae is the most commonly occurring intracellular bacterial pathogen with 
serological studies showing that up to 80% of the world population is or has been 
infected with this organism. Infected individuals can range from asymptomatic and have 
a very mild upper respiratory tract infection which is self-limiting, to more sever upper 
(pharyngitis, sinusitis and otitis) and lower respiratory tract (acute bronchitis, 
exacerbations of chronic bronchitis and asthma and community acquired pneumonia) 
infections. In addition to its role in respiratory disease, C. pneumoniae has been linked 
to chronic cardiovascular inflammatory diseases such as atherosclerosis, abdominal 
aortic aneurisms and valvular lesions. Its role in respiratory infection and atherosclerotic 
disease make C. pneumoniae one of the most widespread and important human 
pathogens, with significant healthcare costs worldwide. In addition to widespread 
infections in humans, C. pneumoniae infections have been reported in a range of warm 
and cold-blooded animals including horses, koalas, bandicoots, frogs and turtles. In 
animal hosts, C. pneumoniae infects a wide range of tissues and are linked to 
respiratory, conjuctival, genitourinary, systemic and vascular diseases. We have 
previously proposed that human C. pneumoniae have originally arisen from at least two 
zoonotic events in the past and that the animal strains appear to be ancestral to human 
strains. The hypothesis which will be investigated in this thesis is that the highly 
successful obligate intracellular pathogen, C. pneumoniae, has actually evolved an 
increasing “susceptibility” to the key amino acid, tryptophan. Rather than making this 
tryptophan auxotroph more vulnerable to host “attack”, it has enabled the evolution of 
the more ancient, animal strains (which are less sensitive to tryptophan availability and 
cause more acute infections) towards the currently successful human strains. This 
project aims to investigate chronic infection by the important intracellular bacterial 
pathogen C. pneumoniae through identifying specific adaptations to host immune and 
antibiotic mediated stress responses.  
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1.2 THE SPECIFIC AIMS OF THE STUDY 
 
1. Characterisation of C. pneumoniae specific adaptation to IFN-γ induced stressor 
in human and animal isolates.  
 
2. Characterisation of C. pneumoniae specific adaptation to penicillin G induced 
stressor in human and animal isolates.       
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2.2 ORIGIN AND TAXONOMY OF CHLAMYDIA PNEUMONIAE 
In 1907, Halberstaedter and Prowazek identified intracytoplasmic inclusions in 
epithelial scrapings from individuals with trachoma and termed them Chlamydozoa after 
the Greek word ‘chlamys’ meaning cloak, in reference to intracytoplasmic inclusion 
draped around the host cell nucleus (Halberstaedter and Prowasek, 1907). Previously, 
the taxonomy of the Chlamydiales was divided into the ‘Old’ Classification and ‘New’ 
Classification (Table 2.1). The ‘Old’ classification was based on distinct biochemical 
traits, morphological features, developmental cycles and host range. In this 
classification, the genus Chlamydia contained four species, C. trachomatis (Moulder et 
al., 1984) infecting humans, swine, mice and hamsters; C. psittaci (Moulder et al., 
1984) infecting mammals, birds, cats and guinea pig; C. pneumoniae (Grayston et al., 
1989) infecting humans and wide range of animals and C. pecorum (Fukushi et al., 
1992) infecting a wide range of mammals (cattle, sheep and goats (ruminants), koalas 
(marsupials), and swine (Table 2.1).  
However, the rapid expansion of organisms within the order Chlamydiales led to the 
proposal of a revision to the Chlamydiaceae taxonomy. In 1999, Everett et al. proposed 
a division of the Chlamydiaceae into two genera; Chlamydia (C. trachomatis, C. 
muridarum and C. suis) and Chlamydophila (C. pneumoniae, C. pecorum, C. felis, C. 
abortus, C. psittaci and C. caviae) based on ribosomal RNA (rRNA) gene sequences 
(Table 2.1) (Everett et al., 1999). This reclassification was supported by some 
chlamydiologists but opposed by many in the field, as the main issues of concern are 
that the 16S rRNA sequence identify thresholds used, do not consistently separate the 
two genera, as well as the absence of clear phenotypic evidence to differentiate between 
Chlamydia and Chlamydophila (Bavoil et al., 2013; Sachse et al., 2015). Therefore, 
based on recent advancements in genome data and biological features, K. Sachse, et al., 
proposed the re-unification of all the 11 currently recognized Chlamydiaceae species 
into a single genus Chlamydia (Table 2.1) (Sachse et al., 2015). In the current thesis, we 
will adopt the most widely accepted taxonomy that defines a single genus, Chlamydia 
and eleven species - Chlamydia abortus, Chlamydia avium, Chlamydia caviae 
Chlamydia felis, Chlamydia gallinacean, Chlamydia muridarum, Chlamydia pecorum, 
Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia suis and Chlamydia 
trachomatis.  
 Chapter 2: Literature Review 23 
C. pneumoniae was isolated in 1965 from the conjunctiva of Taiwanese child 
participating in a trachoma vaccine trail (Grayston, 1965; Kuo et al., 1986) and the first 
pharyngeal isolate was recovered from a student with pharyngitis in 1983. Hence, all 
initial C. pneumoniae isolates were refereed as TWAR (TW183-AR39) strain of C. 
psittaci (Kuo et al., 1986). In 1989, C. pneumoniae was designated its own species 
based on unique EB morphology, DNA analysis and serology (Grayston et al., 1986). 
Table 2.1 Comparison of the different classification systems used in for Chlamydia. 
Pre-1999 Taxonomy  Everett et al. Taxonomy 
 (Everett et al., 1999) 
Current Taxonomy  
(Sachse et al., 2015) 
Family 
Chlamydiaceae  
Genus and Species 
Chlamydia 
• Chlamydia psittaci 
• Chlamydia pecorum 
• Chlamydia 
pneumoniae 
• Chlamydia 
trachomatis 
 
Family 
Chlamydiaceae  
Genus and Species 
Chlamydia  
• Chlamydia 
trachomatis 
• Chlamydia 
muridarum 
• Chlamydia suis  
Chlamydophila  
• Chlamydia psittaci 
• Chlamydia abortus 
• Chlamydia caviae 
• Chlamydia pecorum 
• Chlamydia 
pneumoniae 
• Chlamydia felis 
 
Family  
Chlamydiaceae 
Genus and Species  
Chlamydia  
• Chlamydia abortus 
• Chlamydia avium 
• Chlamydia caviae 
• Chlamydia felis 
• Chlamydia gallinacean 
• Chlamydia muridarum 
• Chlamydia pecorum 
• Chlamydia pneumoniae 
• Chlamydia psittaci 
• Chlamydia suis  
• Chlamydia trachomatis 
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2.3 DISEASES CAUSED BY C. PNEUMONIAE 
Of the eleven species in the genus Chlamydia, C. pneumoniae is arguably the most 
successful pathogen, infecting humans and an amazingly wide range of animals. In 
humans, serological studies show that almost all of the world’s population is, or has 
been, infected with C. pneumoniae (Villegas et al., 2010). Its role in respiratory 
infection and atherosclerotic disease make C. pneumoniae one of the most widespread 
and important human pathogens, with significant healthcare costs worldwide. 
Respiratory infections are most common with sero-epidemiological surveys indicating 
that infection is both endemic and epidemic. Asymptomatic infections are common, 
usually manifesting as mild upper tract infections that are self-limiting, although they 
may progress to more severe upper (pharyngitis, sinusitis, otitis) and lower respiratory 
tract infections (acute bronchitis, exacerbations of chronic bronchitis and asthma, and 
community acquired pneumonia) (Bas et al., 1996; Bauriedel et al., 1999; Bauriedel et 
al., 2000; Beaty et al., 1991; Borel et al., 2006; Clancy et al., 2006; Clementsen et al., 
2002; Cochrane et al., 2003, 2005a , 2005b)). The species was initially “discovered” in 
Finland in 1985 where it caused epidemics of pneumonia in military barracks (Saikku et 
al., 1985), and after its initial worldwide characterisation (Heiskanen-Kosma et al., 
1999; Kauppinen and Saikku, 1995; Kauppinen et al., 1995; Kauppinen et al., 1996), 
was thought to have declined somewhat in prevalence. However, serological studies as 
well as outbreaks in confined populations (Al-Younes, 2013; Conklin et al., 2013) show 
that it is still a widespread and successful respiratory pathogen.  
 
In addition to respiratory infections, C. pneumoniae has been linked with several other 
chronic conditions, most notably cardiovascular inflammatory diseases such as, 
atherosclerosis, abdominal aortic aneurisms and valvular lesions (Haider et al., 2011; 
Haubitz and Brunkhorst, 2001; Hoymans et al., 2002; Jha et al., 2007). Animal model 
studies (rabbits and mice) clearly demonstrate a link between C. pneumoniae infection 
and atherosclerosis and recent cell biology research is beginning to demonstrate 
mechanisms by which this organism directly contributes to the pathogenesis of 
cardiovascular diseases (Campbell and Rosenfeld, 2014). Laboratory based studies 
suggest that C. pneumoniae can induce all of the process involved in atherosclerosis 
(Watson and Alp, 2008). C. pneumoniae elementary bodies are endocytosed by alveolar 
macrophages during local inflammation of the lower respiratory tract, resulting in the up 
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regulation of adhesion ligands which facilitates the adhesion of infected macrophages to 
arterial endothelial cells (Campbell et al., 2012) . In addition, C. pneumoniae gains 
access to the vasculature by infecting circulating monocytes, which results in adhesion 
and trans-endothelial migration (Molestina et al., 1999). Infected monocytes can 
transmit the C. pneumoniae infection to local arterial macrophages, endothelial (Lin et 
al., 2000) and smooth muscles cells (Puolakkainen et al., 2003). Infections of arterial 
macrophages result in the production of pro inflammatory cytokines such as TNF, IL-6, 
IL-1 and transform them into foam cells, which is an early marker of atherosclerotic 
lesions (Campbell et al., 2005; Choroszy-Krol et al., 2014; Prochnau et al., 2004; Rodel 
et al., 2000). Furthermore, the activation of smooth muscles cells, macrophages and 
endothelial cells by chlamydial heat shock protein antigens cHSP60 results in the 
production cytokines and key enzymes, which leads to plaque destabilisation and 
thrombus formation (Cabbage et al., 2014; Kalayoglu et al., 1999; Kol et al., 1998). 
These processes, which affect the atheroma biology, can eventually result in myocardial 
infarction in infected individuals.  
 
In addition to the strong link with cardiovascular diseases, C. pneumoniae has also been 
linked with asthma (Nagy et al., 2007) and chronic obstructive pulmonary disease 
(Karnak and Beder, 2002; Karnak et al., 2001). C. pneumoniae infections can be a 
causative factor which plays an important role in the pathogenesis of asthma (Black et 
al., 2000). C. pneumoniae infections may also induce epithelial and ciliary damage, IgE 
hypersecretion and modulation of immune responses, and cytokine secretion to a 
dominant Th2 phenotype (Hahn et al., 2012; Larché et al., 2003), which leads to 
chronic inflammation and bronchial hyper responsiveness to allergens (Stewart, 2001).  
While there continues to be individual reports of severe respiratory disease associated 
with C. pneumoniae (Chen et al., 2013), it also appears that the norm is now an 
association of C. pneumoniae with a range of chronic diseases like diabetes (Rizzo et 
al., 2012; Wang et al., 2009) Alzheimer’s disease (Balin et al., 1998; Balin et al., 2008), 
arthritis (Hannu et al., 1999), and lung cancer (Jackson et al., 2000; Kocazeybek, 2003; 
Koyi et al., 2001). 
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2.4 HOST RANGE OF C. PNEUMONIAE 
In addition to widespread infections in humans, C. pneumoniae infections has been 
reported in a wide range of warm and cold blooded hosts including horses (Wills et al., 
1990) ,  koalas, (Jackson et al., 1999) bandicoots (Kutlin et al., 2007), frogs (Read et 
al., 2000b) , turtles . This diversity is interesting given that there are less than 1% 
genomic differences between human and animal C. pneumoniae isolates. Analysis of all 
the animal strains using C. pneumoniae-specific fluorescent-antibody staining, cell 
culture and sequencing of the ompA, ompB, 16S rRNA genes demonstrated high 
similarity with the human C. pneumoniae isolates (Bodetti et al., 2002b) (Table 2.2). In 
animal hosts, C. pneumoniae infects a wide range of tissues and has been linked to 
respiratory, conjuctival, genitourinary, systemic and vascular diseases. Acute respiratory 
diseases associated with pneumoniae were reported in horses, mild respiratory disease, 
granulomatous, and pneumoniae were observed in puff adders, excessive quantities of 
subcutaneous and coelomic clear fluid and enlarged nodular kidneys were observed in 
blue mountain tree frogs, and green turtles showed signs of lethargy, anorexia, with 
evidence of necrotising myocarditis and fibrous splenitis (Bodetti et al., 2002b). In 
addition, koala populations affected by C. pneumoniae has been commonly isolated 
from respiratory site with clinical signs including coughing, sneezing, chest congestion, 
rhinitis and in severe cases pneumoniae (Devereaux et al., 2003; Wardrop, 1999). 
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Table 2.2: Summary of hosts and tissue specimens analysed for the presence of 
Chlamydia. Two gene loci were used (16S rRNA and ompA) for the detection 
(Adapted from Bodetti et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Host Tissue sample 
analysed 
Chlamydial 
species similarity 
References and 
geographical 
location of hosts 
Human Throat swabs C. pneumoniae Gaydos et al., 
1992 
Worldwide 
Horse Throat swabs C. pneumoniae Wills et al., 1990 
United Kingdom 
Koala Nasal swabs C. pneumoniae Wardrop et al., 
1999, Australia 
Great barred 
frog 
Respiratory  C. pneumoniae Berger et al., 1999 
Australia 
African Clawed 
frog 
Respiratory C. pneumoniae Reed et al., 2000 
USA 
Blue Mountains 
tree frog 
Lung, heart, 
kidney 
C. pneumoniae Bodetti et al., 2002 
Australia 
Green sea turtle Heart C. abortus, 
Neochlamydia 
Bodetti et al., 2002 
USA 
Chameleon Spleen, liver No 16S rRNA PCR 
product 
Bodetti et al., 2002 
Tanzania 
Burmese 
python 
Lung, liver C. abortus Bodetti et al., 2002 
USA and Europe 
Puff Adder Respiratory 
tissue, heart 
C. pneumoniae,  
C. abortus 
Bodetti et al., 2002 
USA 
Iguana Liver, lung, 
spleen, stomach, 
intestine 
C. pneumoniae, 
 C. felis 
Bodetti et al., 2002 
Central America 
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2.5  C. PNEUMONIAE DEVELOPMENTAL CYCLE 
All the members of the Chlamydiaceae exhibit a unique bi-phasic developmental cycle 
consisting of two stages, the infectious but metabolically non-active elementary body 
(EB), and the non-infectious but metabolically active reticulate body (RB) (reviewed in 
Abdelrahman and Belland, 2005). However, recently a cell-free culture system showed 
that EBs have high levels of metabolic and biosynthetic activity, challenging the 
historically described notion that EBs are metabolically dormant (Omsland et al., 2012). 
Once an EB attaches and enters an epithelial cell it hijacks specific host cell signalling 
pathways (Coombes and Mahony, 2002; Lane et al., 2008). The internalized EB avoids 
phagolysosomal fusion by encasing itself in a membrane bound vacuole called the 
inclusion. At approximately 3 hours post infection, the EB converts into the 
metabolically active RB, and replicates by binary fission over a 24 - 48 hour period 
(Miyashita and Matsumoto, 2004). The inclusion continues to expand simultaneously 
with the increasing chlamydial population and later, at 48 - 72 hour post infection the 
RBs asynchronously converts back to EBs (secondary differentiation). The host cell 
then lyses at about 60 - 96 hour post infection releasing EBs that infects neighbouring 
cells (Fig. 2.1). 
                                    
Figure 2.1 Schematic representation of the chlamydial developmental cycle (taken from 
Abdelrahman and Belland, 2005). 
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2.6 C. PNEUMONIAE PERSISTENCE  
Chlamydia also shows deviations from the normal developmental cycle when exposed 
to a range of stressful conditions (Figure 1.1). The developmental cycle is disrupted 
under stressful growth conditions, caused by co-infections, immunological (e.g. 
interferon gamma exposure), antibiotics and nutrient deprivation stressors (Beatty et al., 
1994a; Beatty et al., 1993; Hogan et al., 2004b; Skilton et al., 2009). This altered 
chlamydial growth phase is characterized by enlarged, pleomorphic RBs termed 
aberrant bodies (AB) which are incapable of binary fission and differentiation back to 
the EBs but are capable of chromosomal replication (suggesting that persistent RBs are 
metabolically viable but non-infectious) (Lambden et al., 2006). Chlamydiae may exist 
in this altered state in the host for months or even years and are often asymptomatic 
during this association. These changes are reversible as the removal of the stressors lead 
to resumption of chlamydial growth and the release of infectious EBs (Rottenberg et al., 
2002). The ability to cause a persistent infection is thought to be one of the major 
factors involved in the pathogenesis of chlamydial diseases (reviewed in Hogan et al., 
2004b).  
 
Persistence, which has been more comprehensively characterised in closely related 
Chlamydia (C.) trachomatis, is typified by extended association of the organism with 
the host cells in a viable but non - culturable form. Whilst many of the persistent models 
have been conducted in C. trachomatis, persistence may well have been the underlying 
mechanism that leads to chronic disease in humans in the case of C. pneumoniae. There 
are already distinctions between the two species (C. pneumoniae and C. trachomatis), 
with C. pneumoniae more able to infect or even propagate in some host immune cells, 
which may facilitate systemic dissemination (Abdul-Sater et al., 2010; Azenabor and 
Chaudhry, 2003; Beagley et al., 2009), and evidence or isolation of C. pneumoniae from 
a range of tissue chronic disease sites has helped build the possible association with 
chronic disease (Bauriedel et al., 1999; Bauriedel et al., 2000). Accordingly, it has been 
established that IFN-γ induction of IDO expression can induce persistence of C. 
pneumoniae in HEp-2 cells (Mehta et al., 1998), aortic smooth muscle cells (Pantoja et 
al., 2000b, 2001), and endothelial cells (Bellmann-Weiler et al., 2010), but not in 
lymphocytes (Ishida et al., 2013). Additionally, it has been established that penicillin 
and iron limitation, can also induce persistence in HeLa cells (Klos et al., 2009b).  
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Gene expression array data supports that the C. pneumoniae persistence models involve 
continued DNA replication that is uncoupled from cytokinesis (Byrne et al., 2001). 
During persistence, it has been suggested that specific chlamydial genes are 
differentially regulated in C. trachomatis and C. pneumoniae. Although transcriptional 
responses depend on the chlamydial species, host cells and the in vitro method used to 
induce persistence, there are a few common patterns between different persistence 
models (Klos et al., 2009a). Chlamydial genes related to cell division and ‘late genes’ 
that are specially expressed late in the developmental cycle are down regulated during 
persistence due to the inhibition of RB to EB differentiation. Genes that are commonly 
down regulated include hctB, omcB, ompA and crpA whereas the htrA gene is mostly 
unregulated in different persistence models (Hogan et al., 2004b; Schoborg, 2011). The 
expression of the cysteine rich protein, encoded by omcB, is abundant in the EB 
envelope and the histone like protein 2 encoded by hctB are both down regulated after 
antibiotics exposure (Goellner et al., 2006; Lambden et al., 2006). 
 
Chlamydia species have several distinguishing morphological features including the 
inclusion morphology, compression of the host cell nucleus, and EB morphology and 
glycogen accumulation within the inclusion (Fig 2.2). The inclusion morphology varies 
from simple round structures (C. pneumoniae) to irregular and lobular morphologies (C. 
caviae), which presumably are the result of host adaptations, access to nutrients and 
biogenesis and maintenance of outer membrane proteins (Spears and Storz, 1979; 
Miyashita and Matsumoto, 2004). 
 
EBs are all enclosed within a cytoplasmic membrane and are relatively stable against 
mechanical agitation (Miyashita and Matsumoto, 2004). The C. pneumoniae isolates 
having the pear shaped EB morphology are TW-183 (Chi et al., 1987), AC-43 
(Yamazaki et al., 1992), and AR-388 (Miyashita and Matsumoto, 2004). And 
C.pneumoniae isolates having round outer membranes are horse isolate N16 (Wills et 
al., 1990), frog isolate GBF (Berger et al., 1999), human isolates YK-41 (Miyashita et 
al., 1993), LKK-1 (Lee et al., 2003), IOL-207 (Carter et al., 1991), Kajaani-6 (Popov et 
al., 1991). The RB morphology is consistently round across the geographically 
widespread C. pneumoniae isolates (Miyashita and Matsumoto, 2004; Popov et al., 
1991; Berger et al., 1999).  
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Figure 2.2 Thin sections of C. pneumoniae (A) TW-183; (B) AR-39; (C) AR-388 and (D) YK-41 
inclusions in HeLa 229 cells at 72 h post-inoculation (taken from Miyashita et al., 1993). Strain YK-
41 EBs are round; those of strains TW-183, AR-39 and AR-388 are enclosed by a wavy outer 
membrane and are “pear-shaped” in profile (E) Ultrastructural analyses of brain tissues from 
Alzheimer’s disease patients to characterize the morphologies of C. pneumonia (taken from Arking 
et al., 1999). (F) Transmission electron micrograph of chlamydial particles at various stages in lung 
tissue (taken from Berger et al., 1999). (G) Transmission electron micrographs of C. pneumoniae 
Koala LPCoLN inclusion development in HEp-2 cells at 48 h (taken from Mitchell et al., 2008). (H) 
Transmission electron micrograph of chlamydial particles in liver from a captive African c lawed 
frog (Xenopus tropicalis) (taken from Read et al., 2000). 
 
2.7  CHLAMYDIAL METABOLIC REQUIREMENTS 
The metabolic reactions have been categorized in to four groups: 
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Assembly reactions involve the chemical modification of macromolecules (RNA, 
DNA, protein, phospholipid, lipopolysaccharide, peptidoglycan) and their association to 
form cellular structures (Neidhardt et al., 1990). 
 
Polymerization reactions involve the linkage of activated molecular building blocks 
(nucleotides, amino acids, fatty acids and various sugars) into macromolecules. The 
genome sequence reveals that Chlamydia contains a basic set of enzymes for DNA 
replication, RNA transcription and translation. It also has the enzymatic machinery to 
carry out polymerization reactions typical of prokaryotes and that their growth is 
independent of functional host polymerization reactions(McClarty, 1994). Major 
pathways for DNA repair, including uvr excision repair, mutL/mutS mismatch repair, 
mutY, nfo,nth and ada are also present (Zhang et al., 1995).  
 
Glycogen 
Glycogen is a branched, glucose-containing polysaccharide, which represents a major 
carbon and energy reserve in many bacteria. Several enteric bacteria and bacilli are 
known to accumulate glycogen when cell growth becomes limited by nitrogen but 
carbon is still available (Smith, 1992).The biological function and regulation of 
glycogen metabolism in Chlamydia is poorly understood. Glycogen, which can be 
visualized with iodine staining, has only been detected in the inclusion of C. 
trachomatis and not in C.  psittaci or C. pneumoniae (Matsumoto et al., 1998; Moulder, 
1991). The accumulation of glycogen within C. trachomatis inclusions is associated 
with the presence of chlamydial plasmid whereas the plasmid-deficient C. muridarum, 
show impaired accumulation of glycogen within inclusions (O'Connell et al., 2011). C. 
trachomatis contains homologues for all the genes required for synthesizing glycogen 
(mrsA, glgC, glgA and glgB) from glucose-6-phosphate (Stephens et al, 1998; Read et 
al, 2000; Nguyen et al., 2012). In addition, C. trachomatis also contains orthologues for 
the glycogen-degrading enzymes glycogen hydrolase (GlgX) and glycogen 
phosphorylase (GlgP) which implies that C. trachomatis can not only synthesize and 
store glycogen, but can also break it down to obtain glucose-1-phosphate. Surprisingly, 
despite the fact that C. pneumoniae and C. psittaci strain GPIC are not known to 
accumulate glycogen, their genomes contain an identical complement of glycogen-
metabolizing genes. When C. trachomatis infected HeLa cells were cultured in a 
medium containing various glucose concentrations or in the presence of gluconeogenic 
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carbon sources, the amount of carbon available in the medium affected only chlamydial 
glycogen accumulation with no significant change in the expression of genes required 
for glycogen metabolism. Thus, it was proposed that Chlamydia is unable to alter the 
expression of genes involved in carbon metabolism in response to changes in 
environmental (McCarty et al., 2000) and that glycogen accumulation may not be 
essential for chlamydial survival. However, it is also speculated that glycogen may 
enhance chlamydial attachment or invasion and that loss of glycogen biosynthesis, as a 
consequence of the failure to transcribe glgA, might impair infectivity in vivo (Carlson 
et al., 2008; O'Connell et al., 2011) 
 
Lipids 
Chlamydia uses isoleucine as a lipid precursor, which serves as the source of carbon for 
the initial primer for branched chain fatty acid biosynthesis (Kaneda et al., 1991). 
Chlamydia also contains phospholipids from both prokaryote membranes 
(phosphatidylethanolamine, cardiolipin, phosphatidylglycerol) and eukaryotic cell 
membranes (sphingomyelin, phosphatidylcholine, phosphatidylinositol, 
phosphatidylserine), which are trafficked from the host cell to chlamydiae (Hackstadt et 
al., 1995, 1996, 1997; Scidmore et al., 1996). 
 
Lipopolysaccharide 
Lipopolysaccharide (LPS) is the principle component of the outer membrane of Gram-
negative bacteria (Raetz et al., 2007). It forms a tight permeability barrier that excludes 
cell-damaging agents such as detergents, proteases, bile salts, and hydrophobic 
antimicrobials. LPS consists of a hydrophobic membrane anchor lipid A, a non-
repeating core oligosaccharide, and a distal polysaccharide. Chlamydial LPS is 
technically a lipooligosaccharide (LOS), because it only consists of a trisaccharide core 
of 3-deoxy-D-manno-oct-2-ulopyranosic acid (Kdo), linked to pentaacyl lipid A (Rund 
S, 1999). In addition, chlamydial lipid A contains longer, nonhydroxylated fatty acids 
that significantly reduce its activity as an endotoxin (Heine et al., 2007 ). The 
chlamydial genome contains genes for KDO synthesis (kdsA,kdsB),  and also the ability 
to synthesize the glucosamine disaccharide backbone of lipid A from the glycolytic 
intermediate fructose-6-phosphate as well as the enzymes required for the fatty 
acylation reactions. An interesting finding by Nguyen et al., (2011) showed that LpxC 
inhibitors can act as a potent antichlamydial agent. (LpxC, a zinc-dependent 
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cytoplasmic deacetylase that catalyzes the first committed step in lipid A biosynthesis). 
In the presence of LpxC, C. trachomatis replicative reticulate bodies accumulated in 
enlarged inclusions but failed to express selected late-stage proteins and transition to 
elementary bodies, the chlamydial developmental form that is required for invasion of 
mammalian cells (Nguyena et al., 2011). 
 
Peptidoglycan 
Peptidoglycan is an important structure in the bacterial cell wall and plays a critical role 
in cell division and in maintaining the integrity of cell shape and osmotic pressure (Egan 
and Vollmer, 2013). Penicillin acts on PG -containing bacteria by binding to the 
penicillin binding proteins (PBP’s), resulting in the blockage of PG biosynthesis 
(Chattaway, 1982; Russell and Chopra, 1996). Studies have suggested that penicillin 
inhibits chlamydial cell division by binding to PBP2 and PBP3/Fts1 (Ouellette et al., 
2012). The Chlamydiaceae genome analysis revealed a nearly complete PG 
biosynthesis pathway including the presence of enzymes linked to both the cytoplasmic 
steps (MurA, MurC/Ddl, CT390, DapF, MurE, GlyA and MurF) and membrane linked 
steps (MraY and MurG) for PG biosynthesis (McCoy et al., 2006; McCoy and Maurelli, 
2006; Patin et al., 2012). Although, Chlamydiales are susceptible to anti-PG antibiotics 
and the fact that they contain many genes in the PG biosynthesis pathway, all attempts 
to detect or purify PG in Chlamydia were largely unsuccessful (Barbour et al., 1982; 
Chopra et al., 1998; Fox et al., 1990; Hatch, 1996; Moulder, 1993). As a result, the 
existence of PG in Chlamydia has been controversial and has often been referred to as 
the ‘chlamydial anomaly’ (Moulder, 1993). Recently, Maurelli and colleagues (Liechti 
et al., 2014) proved the presence of functional PG in C. trachomatis by metabolically 
labelling chlamydial PG and using click chemistry. Their study used a novel D-amino 
acid dipeptide probes to covalently label the PG of actively growing Chlamydia and 
showed that the chlamydial PG is localized to the septum of dividing RBs. Furthermore, 
this study demonstrated PG production in C. trachomatis as early as 8 hour post 
infection, confirming previous transcriptome data (Albrecht et al., 2010, 2011; Belland 
et al., 2003; Omsland et al., 2012; Shaw et al., 2000) which showed the up regulation of 
PG biosynthesis genes during early stages of EB to RB transition (Belland et al., 2003), 
thus indicating the possible importance of PG in chlamydial growth and cytokinesis 
(Egan and Vollmer, 2013). 
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Biosynthetic reactions produce the building blocks of polymerization reactions as well 
as numerous coenzymes and related metabolic factors. In chlamydiae, the biosynthetic 
capabilities are greatly reduced and instead numerous transport systems, broad substrate 
specificity are present. 
 
Amino Acid Metabolism 
Several studies on chlamydiae demonstrate strain-to-strain variation in amino acid 
requirements (Hatch et al., 1988; Moulder et al., 1991). Genome sequence of C. 
trachomatis implies the presence of few genes for amino acid biosynthesis and only a 
small number of amino acid transporters, which exhibit broad substrate specificity. The 
native amino acid biosynthesis pathways are frequently truncated, giving rise to end 
products that function as intermediates in other biosynthetic pathways. For example, 
instead of synthesizing phenylalanine/tyrosine, the pathway terminates with chorismate, 
which acts as an intermediate in the synthesis of folates and ubiquinone. Likewise, the 
lysine pathway truncates at meso-diaminopimelate, a component of the pentapeptide 
moiety of peptidoglycan. Two broad specificity transaminases, aspC and tyrB in 
Chlamydia, are involved in the biosynthesis of amino acids and in balancing the 
dicarboxylate pool (Neidhardt et al., 1990).  
 
Complete genome sequences of now more than 20 chlamydial isolates show the 
conservation of many genes with exception of a region termed the Plasticity zone (PZ) 
(Read et al., 2000). Tryptophan biosynthesis encoding genes are present in this zone. C. 
pneumoniae and C. muridarum do not contain any tryptophan biosynthesis genes, 
whereas C.trachomatis contains trpA, trpB and trpR encoding α, β subunits of 
tryptophan synthase genes and Tryptophan repressor (TrpR), respectively. An 
interesting finding is the connection between cytoplasmic IFN-γ and tryptophan. Studies 
from Beatty et al., 1994, demonstrated the ability of IFN-γ to block chlamydial growth. 
A key mechanism to control chlamydial growth is the production of IFN-γ by CD4+T 
cells (Beatty et al., 1994; Loomis et al., 2002). IFN-γ stimulates indoleamine 2, 3-
dioxygenase ( Nguyena et al. 2011), which catalyses the breakdown of tryptophan to 
kynurenine, resulting in the utilization of intracellular tryptophan. However, different 
species and serovars display different sensitivities to IFN-γ (Morrison, 2000). The C. 
trachomatis genome does not contain the homologs for all the enzymes required for 
tryptophan biosynthesis. It can produce chorismate, but cannot proceed to next step due 
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to lack of homologs of trpE and trpD. However, it can convert phosphoribosyl 
anthranilate to tryptophan with the help of homologs of trpA/B/C. Chlamydia cannot 
even utilise phosphoribosyl anthranilate for bypassing the lack of TrpE/D/F enzymes 
since even host cell are devoid of tryptophan machinery. It is a very interesting question 
as to the source of tryptophan for Chlamydia. It has even got TrpR homolog. TrpR is an 
aporepressor. When tryptophan binds to TrpR, it alters its confirmation such that it can 
bind to operator genes, leading to reduction in its expression. C. pneumoniae is one of 
the chlamydial species that does not contain any genes in this pathway.  
 
 Fatty acid metabolism 
The C. trachomatis genome contains homologs for all the genes required to carry out 
long chain fatty acids synthesis (acc and fab gene products) and branched chain fatty 
acid synthesis (odbA, aceF, and lpd)(Stephens et al., 1999). 
 
Nucleotide metabolism 
Nucleotides are synthesized either by de novo or salvage pathways. Various studies 
conducted on chlamydial nucleotide metabolism using both host free RBs or an in situ 
approach (Hatch et al., 1975, 1988; Hayashi et al., 1996; McClarty et al., 1994, 1991) 
demonstrate that chlamydiae cannot synthesize nucleotides by de novo or salvage 
pathways. Recently it was reported that chlamydiae are actually auxotrophic only for 
ATP, GTP and UTP (Graham et al., 1993). Although CTP can be transported from the 
host cell, chlamydiae can synthesize it de novo via CTP synthetase (pyrG) (Tipples et 
al., 1995; John et al., 1996). The chlamydial adt2 gene (translocase homolog) was 
shown to possess NTP-transporting capabilities when expressed in E. coli (Winkler et 
al., 1999). In contrast to ribonucleotides, several studies (Hatch et al., 1988; McClarty 
et al., 1991; Moulder et al., 1991) revealed that Chlamydia cannot transport dNTPs. 
Three of the dNTPs are produced by the action of ribonucleotide reductase (Reichard et 
al., 1993, 1997), whereas dTTP is synthesized by the action of both ribonucleotide 
reductase and thymidylate synthase (Montfort et al., 1997). Among all the genomes 
sequenced to date, chlamydiae have a surprisingly small repertoire of genes encoding 
enzymes for nucleotide biosynthesis. In particular, there is a lack of PRPP synthase, an 
essential enzyme for de novo and salvage pathways. Homologs of monophosphate 
kinases (amk,cmk, gmk, pyrH, and tmk) which produce diphospahtes from 
monosphosphates are present in chlamydiae. In addition, homologs of genes nucleoside 
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diphosphate kinase (ndk) which converts diphosphates to triphosphates, ribonucleotide 
reductases (NrdA and NrdB) and thioredoxin (Trx) are present. 
 
Fueling reactions produce the key metabolic precursors for most biosynthetic pathways 
as well as the reducing power and metabolic energy needed for biosynthesis and 
polymerization. Metabolic precursors such as ATP, NADPH, acetyl-CoA, and 
Phosphoenolpyruvate (PEP) supply energy and reducing power to drive metabolic 
reactions. Chlamydiae possess the enzymatic machinery needed to synthesize all the 12 
precursor metabolites by a series of reactions. These reactions are divided into Embden-
Meyerhoff-Parnas (EMP) pathway, which converts glucose-6-P to pyruvate, the pentose 
phosphate pathway (PPP),which oxidizes glucose-6-P to CO2; and the tricarboxylic 
acid (TCA) cycle, which oxidizes acetylCoA to CO2  (Moulder et al., 1991; Hatch et 
al., 1988). 
2.8 C. PNEUMONIAE GENOME   
The chlamydial genome ranges in size from 976kb to around 1.2 MB (1,042,519bp to 
1,230,230bp) which is relatively small compared to other bacteria (Kalman et al., 
1999b; Stephens and S.Kalman, 1988). The genome size of the Chlamydia-like 
organism Protochlamydia amoebophila, UWE25 isolated from a soil sample is 2.4 MB, 
twice the size of the pathogenic Chlamydia (Collingro et al., 2005; Horn et al., 2004). 
The host-pathogen relationship is thought to be the major factor leading to genome 
reduction, as much of the supply of energy, nutrients and metabolites can be obtained 
directly from the host. Even though P. amoebophila has a complete type three secretion 
effectors (T3SS) and chlamydial protease like activity factor (CPAF), the clear 
evolutionary distance between the strains is evident by the lack of major outer 
membrane protein (MOMP) homologs, a key functional and immunological component 
of the current pathogenic Chlamydia. Since the first full chlamydial genome sequence 
of C. trachomatis serovar D by Stephens et al., (1998), 17 full chlamydial genomes 
have been published. These genomes are six C. trachomatis (434/Bu, A/HAR-13, 
D/UW-3/CX, Jail20, L2b/UCH-1/proctitis, and TW5/OT), six C. pneumoniae (AR39, 
CWL029, J138, TW183, LPCoLN and B21), three C. muridarum (MopnTet14, Weiss 
and Nigg), one C. caviae (GPIC), one C. abortus (S26/3) and one C. felis (Fe/C-56) 
genome (Bachmann et al., 2014). 
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Comparative genome analysis of chlamydial species has revealed some powerful 
findings   (Carlson et al., 2005). Comparisons of C. trachomatis oculartrophic isolate 
A/HAR-13 and C. trachomatis genitotrophic D/UW-3 (Stephens et al., 1998) isolate 
showed 99.6% sequence identity, confirming that the presence of active synthase gene 
on serovar A and the chlamydial protein toxin are the major tissue tropisms exhibited by 
the two serovars. The genome sequence of C. muridarum isolates Weiss (Ramsey, 
2009), Nigg (Read et al., 2000) and Nigg2 are well conserved at  the DNA level but still 
showed major phenotypic differences; with Weiss isolate displaying greater virulence at 
both intravaginal as well as respiratory sites in the mouse. 
The four human C. pneumoniae genomes (AR39-Read et al., 2000, CWL029-Kalman et 
al., 1999, J138-Shirai et al., 2000 and TW183-Geng et al., 2003) are highly conserved 
in gene order and organisation and share greater than 99.9% sequence identity, with few 
deletions and less than 300 single nucleotide polymorphisms (SNPs) across the genome. 
The near clonality of C. pneumoniae human isolates suggests that the presently 
circulating human strain was recently transmitted to humans from another host. Thus, it 
is hypothesized that C. pneumoniae evolved from an animal pathogen and the C. 
pneumoniae animal isolates are the ancestors of the human isolates; suggesting a recent 
transmission to humans through successive bottlenecks some 150,000 years ago. A lack 
of detectable variation in 17 human C. pneumoniae isolates emphasizes the 
extraordinary genetic conservation of this species. Thus, SNPs have proven useful as a 
sensitive marker to gain new insights into genetic diversity, population structure and 
evolutionary history of C. pneumoniae (Rattei et al., 2007). The partial sequence 
analysis of C. pneumoniae isolates of Koala (LPCoLN from Australia) and Frogs 
(DE177 from Africa and GBF from Australia) revealed that the Koala LPCoLN and 
frog GBF isolates were identical in sequence analysis and were more closely related to 
the frog DE177 isolate (Berger et al., 1999, Hotzel et al., 2001).  
 
Comparative analysis of fully sequenced C. pneumoniae Koala LPCoLN (Myers et al., 
2009) and four previously sequenced human isolates showed some key differences. The 
role of the cryptic plasmid is still unknown in chlamydial biology however it is present 
in some chlamydial species, such as all C. trachomatis isolates, C. pneumoniae 
LPCoLN, C. muridarum MoPn isolate, C. felis Fe/C-56, C. caviae GPIC isolate (Azuma 
et al., 2006; Thomas et al., 1997; Read et al., 2003; Pickett et al., 2005). All human 
derived C. pneumoniae isolates studied to date lack the plasmid, although the Koala 
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LPCoLN isolates carries a full-length chlamydial plasmid, encoding all eight CDSs 
described. In human isolates these CDSs are fragmented forming clusters of functional 
pseudogens. 
 
There have also been some observations, which have correlated the genetic differences 
between human C. pneumoniae isolates to tissue tropism. The genotypic differences in 
tyrosine permease (tyrP) copy numbers and coding sequences has been linked to tissue 
tropism in human C. pneumoniae isolates (Gieffers et al., 2003b). A single copy of tyrP 
gene in human C. pneumoniae has been associated with cardiovascular tropism whereas 
multiple copies of this gene have been putatively linked to respiratory and brain isolates 
(Chacko et al., 2015; Gieffers et al., 2003b). While this is an interesting observation, the 
biochemical activity of chlamydial tyrP protein is still unknown. The other major 
genetic differences are related to the polymorphic membrane proteins pmpE and pmpG 
orthologs and orthologs of inclusion membrane proteins family (inc), which are 
extensively fragmented in the human isolates. This loss of several functional pmp and 
inc genes in the human derived C. pneumoniae isolates, suggests the adaptation to the 
human host. Thus, based on this information our group proposed that C. pneumoniae 
was originally an animal pathogen that crossed the species barrier to humans through 
ongoing reductive evolutionary processes (Mitchell et al., 2010b). This could also be a 
possible explanation of the reported in vitro faster growth rate of Koala LPCoLN isolate 
as compared to human isolate AR-39 (Mitchell et al., 2009).  
 
Several reviews have emerged recently (Aiyar et al., 2014; Lo et al., 2012) suggesting 
that the chlamydial genus as a whole may have evolved a mechanism that mutes or 
down-regulates selected gene products via the tryptophan levels in these key proteins.  
Those proteins that are required during the acute or active growth phase (i.e. normal 
development of Chlamydia) have higher tryptophan content, since tryptophan 
availability is less of an issue in this stage of growth. However, when the host responds 
to chlamydial infection by producing IFN-γ, and tryptophan is depleted, these proteins 
become a burden to the Chlamydia and this triggers their switch from the acute to the 
persistent phase. In the persistent phase, a different sub-set of proteins are required and 
these have a lower tryptophan content (at least the high tryptophan-containing proteins 
are not highly expressed in this phase), making these proteins less of a metabolic burden 
to produce during a time when tryptophan levels are limited. While this hypothesis 
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seems to fit the C. trachomatis data best, it may also be supported by the limited C. 
pneumoniae data that is available. Lo et al. (2011) reported that MurA is a low 
tryptophan-containing enzyme, making it more suited to expression during persistence. 
Indeed, when Timms et al. (2009), evaluated murA transcription in the IFN-γ, model of 
C. pneumoniae, they found that it was up-regulated 2-fold under these conditions 
(Timms et al., 2009). While this hypothesis is appealing, at this stage there is only 
limited bioinformatics data to support it and as yet, very little biological proof. In 
addition, while it might be a general strategy used by chlamydiae, a comparison of the 
human and animal C. pneumoniae genomes does not support an extension of this 
tryptophan skew in the ‘acute’ animal strains. 
2.9 MODULATION OF HOST CELL PROCESSES BY CHLAMYDIA  
The unique “acute” developmental cycle has both strengths and weaknesses. Once 
inside a suitable host cell, provided the chlamydiae can subvert several key host cell 
pathways, they generally have access to a rich pool of nutrients required for growth.  
While the chlamydiae have retained a diverse set of metabolic pathways, they have also 
lost many pathways, making them dependent on their host cell for a significant number 
of key nutrients and intermediates.  A number of EB surface components have been 
proposed as potential ligands mediating initial attachment of chlamydial organisms to 
the host epithelial cells. OmcB is found only on the EBs cell wall complex and could be 
a possible receptor for heparin sulphate –like glycosaminoglyan (Di Pietro et al.), which 
is involved in the initial interaction between the EB and the host cell surface (Su and 
Caldwell, 1991). The chlamydial major outer membrane protein (MOMP) and 
Polymorphic membrane protein (Pmp) D have been shown to neutralize chlamydial 
infectivity in vitro (Crane et al., 2006). Therefore these proteins play a major role as 
adhesins. 
 
Pre-existing molecules in EBs such as tyrosine phosphorylated proteins (TARP) and the 
protein encoded by CT694 genes are injected into the non-phagocytic epithelial cells by 
the type three secretion system (T3SS).  In C. pneumoniae and C. caviae, these early 
host signalling proteins result in the actin cytoskeleton reorganization of host cells 
leading to EB internalization (Clifton et al., 2004; Engel et al., 2004 (Hower, 2009). At 
the early stage of infection, the pre-existing molecules also contribute to the survival of 
the internalized EBs, before the newly synthesized proteins are secreted by RBs. 
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Inclusion membrane proteins (Incs) are provided to chlamydial type III secretion system 
to mediate vesicle fusion, formation of tubular extensions out of inclusions, and 
modulating host cell signalling pathways (Rockey et al., 1995; Hackstadt et al., 1999; 
Rzomp et al., 2003, 2006). Bannantine et al., 2000 and Toh et al., 2003 used 
bioinformatics based approach to predict around 50 C. trachomatis and 100 C. 
pneumoniae localized inclusion membrane proteins (Bannantine et al., 2000; Toh et al., 
2003). 
 
Three C. trachomatis proteases [chlamydial proteasome/protease-like activity factor 
(CPAF), tail-specific protease (Tsp), and chlamydial high temperature requirement 
protein A (cHtrA)] have been shown to be secreted by the sec dependent pathway into 
the infected host cytosol. CPAF prevents the infected host cells from undergoing 
apoptosis or host immune detection and attack via degradation of the pro-apoptotic 
BH3-only proteins. Chlamydia Tail specific protease (Tsp) cleaves NF-kB p65, thus 
silencing the NF-kB mediated inflammatory pathway, which has more detrimental 
effects on chlamydial infection. However, Chlamydia uses the MAP kinase pathway for 
the acquisition of host nutrients, during which inflammatory cytokines, including IL-1, 
IL-6, IL-8, and TNF α are inevitably activated (Lad et al., 2007; Su et al., 2004; Xiao et 
al., 2005).  In addition to this, C. trachomatis encodes two proteins ChlaDub1 and 
ChlaDub2, which inhibit the degradation of IκBα resulting in the blockage of NF-κB 
activation (Le Negrate et al., 2008; Misaghi et al., 2006). Although, C. pneumoniae 
lacks these effector proteins (ChlaDub1 and ChlaDub2), IL-17 induced NF-κB 
activation (a key host immune response to microbial infection of lung) is inhibited by C. 
pneumoniae specific inclusion membrane protein CP0236. Interaction of C. pneumoniae 
specific inclusion membrane protein CP0236 with NF-κB activator 1 (Act1) alters the 
recruitment of Act1 to one of the heteromeric receptor complex (IL-17RA), inhibiting 
IL-17 activation which in turn blocks NF-κB activation (Wolf et al., 2009b). Thus, 
chlamydiae have evolved sophisticated mechanisms to maintain a favourable habitat for 
its intracellular growth while avoiding harm to the infected host cell. 
2.10 TRYPTOPHAN IS AN ESSENTIAL AMINO ACID AND A CENTRAL 
REGULATOR FOR CELL BIOLOGY 
Humans and animals lack the ability to synthesise the essential amino acid tryptophan. 
Consequently tryptophan depletion acts as a major cellular signal. In humans, 
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tryptophan depletion is associated with depression and other neurological consequences 
(Feder et al., 2011; Mace et al., 2011). At a cellular level, reduction of intracellular 
tryptophan pools initiates molecular stress response pathways (via GCN2 kinase and 
mammalian target of rapamycin (mTOR) signalling molecules), resulting in blockage of 
ribosomal translation and cell cycle arrest. Localised tryptophan deprivation can also 
initiate these stress response pathways in local T cells, leading to arrest and the 
promotion of regulatory T cell differentiation. Furthermore, bioactive tryptophan 
metabolites (produced from the kynurenine pathway (Fig 2.3)) have been found to have 
direct immunosuppressive capabilities, facilitating promotion of regulatory T cell 
differentiation (reviewed in (Fallarino et al., 2012; Munn and Mellor, 2013)). In spite of 
these consequences, animal cells in a pathogen defence strategy also actively deplete 
tryptophan. Most bacteria are able to synthesise tryptophan and can partially, overcome 
the host’s efforts to starve it of tryptophan. However, some microbes, such as 
Chlamydia, are full or partial tryptophan auxotrophs.  In fact, Chlamydia has unique 
host and tissue niche specific requirements, intrinsically based on differential abilities to 
synthesise tryptophan (or not) from metabolites or bio-available intermediates.   
2.11  ROLE OF TRYPTOPHAN AND INTERFERON GAMMA IN 
CHLAMYDIAL BIOLOGY 
More than two decades ago tryptophan depletion, via IFN-γ induction of IDO, was 
described as a possible mechanism for inhibiting intracellular growth of the parasite 
Toxoplasma (T.)  gondii (Pfefferkorn, 1984). The simplistic paradigm of IDO being a 
host innate defence mechanism, using essential amino acid deprivation as a means to 
control tryptophan auxotrophic intracellular pathogen replication, has been superseded 
recently by a more complex model. Specifically, the model suggests not just metabolite 
limitation but also that the aforementioned IDO-tryptophan depletion signalling 
functions can be defence mechanisms. Consequently, IDO-tryptophan depletion has 
been found to have an important role in parasitic (Murray et al., 1989), viral (Adams et 
al., 2004), and bacterial (Byrne et al., 1986a; Byrne et al., 1986b) infections. Although 
most reports document pathogen sensitivity to tryptophan depletion, recent studies are 
finding a role for IDO activity in chronic or persistent disease. In particular, IDO-
tryptophan directed immunosuppression is thought to play a role in Leishmania (L.) 
major (Divanovic et al., 2012), Human Immunodeficiency Virus (reviewed in (Boasso, 
2011)), Hepatitis C Virus (Larrea et al., 2007; Rollier et al., 2007), Human Papilloma 
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Virus (Mittal et al., 2013), Listeria monocytogenes (Popov et al., 2008), Mycobacterium 
tuberculosis (Desvignes and Ernst, 2009), Candida albicans (Cheng et al., 2010), and 
Aspergillus fumigatus infections (Montagnoli et al., 2006). Importantly, a recent study 
investigating the role IDO plays in two protozoal infections, T. gondii and  L. major, 
found that IDO facilitates T. gondii clearance and suppresses L. major clearance, 
highlighting the opposing and pathogen specific role that IDO can have in infectious 
disease (Divanovic et al., 2012). 
 
Chlamydial infection of mucosal epithelial cells results in activation of innate, pathogen 
sensing, PRRs. Activation of these receptors initiates an immunological cascade, 
resulting in expression and secretion of cytokines and chemokines (reviewed, (Shimada 
et al., 2012a)), and recruitment of leukocytes (NK cells, neutrophils, macrophages, 
dendritic cells) to the infected tissue (Roan and Starnbach, 2008). An adaptive immune 
response is then initiated via antigen processing cells presenting chlamydial antigens to 
T cells in local lymph nodes. Animal studies (Farris and Morrison, 2011; Rank and 
Whittum-Hudson, 2010; Rothfuchs et al., 2004a; Rothfuchs et al., 2004b)), and to a 
certain degree, human studies (Batteiger et al., 2010; Farris and Morrison, 2011; Halme 
et al., 2000; Rank and Whittum-Hudson, 2010; Rothfuchs et al., 2004a; Rothfuchs et 
al., 2004b), have found that IFN-γ producing T cells are essential for resolution of 
chlamydial infections (Bastidas et al., 2013; Brunham and Rey-Ladino, 2005; Roan and 
Starnbach, 2008). 
 
The anti-chlamydial effect of IFN-γ is attributed predominantly to direct inhibition of 
intracellular growth. IFN-γ results in the induction of myriad of responses in host cells 
(Pawliczak et al., 2005). However, it is the induction of indoleamine 2,3-dioxygenase 
(Nguyena et al., 2011) (Gupta et al., 1994), inducible nitric oxide synthase (iNOS) 
(Igietseme et al., 1997), and down regulation of transferrin receptors (Freidank et al., 
2001) that are central to intracellular inhibition of chlamydial growth. IDO is a heme-
containing, cytosolic, IFN-γ inducible enzyme that catalyses the breakdown of the 
essential amino acid tryptophan to kynurenine via the cleavage of the pyrrole ring (Fig 
2.3). Kynurenine is then released from the cell or further metabolised to the downstream 
catabolites; 3-hydroxykynurenine, 3-hydroxyanthranilic acid, Quinolinic acid and 
finally nicotinamide adenine dinucleotide (NAD) (i.e. the kynurenine pathway) (Fig 
2.3).  
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Figure 2.3 Indoleamine 2, 3 dioxygenase induced tryptophan catabolism along the kynurenine 
pathway (Lob et al., 2009). 
 
Tryptophan availability appears to be the key host specificity and a potential virulence 
mechanism for Chlamydia. The ability to synthesise tryptophan is not universal in the 
family of Chlamydiaceae, (Akers and Tan, 2006; Fehlner-Gardiner et al., 2002a) and 
different chlamydial species have various components of the tryptophan biosynthetic 
pathways that enable them to respond to tryptophan starvation. C. trachomatis strains 
are missing most of the tryptophan biosynthetic pathway but do possess the trpBA 
operon, which codes for the enzyme tryptophan synthase. The genital strains of C. 
trachomatis have a functional tryptophan synthase, which enables them to rescue 
tryptophan from indole, a compound which is produced by the genital tract micro flora 
and hence this explains how the genital strains of C. trachomatis can infect genital tract 
epithelial cells and survive the interferon gamma driven tryptophan depletion by the 
host. The C. muridarum genome contains a Yop-T like cytotoxin, which inactivates the 
p47GTPase, enabling the mouse strain to effectively survive and grow in murine cells 
but not in human cells since they do not have trpBA genes and also mouse cells do not 
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produce indole as their mechanism to deplete the tryptophan (Kalman et al., 1999b; 
Read et al., 2000b; Thomson et al., 2005). All the fully sequenced human C. 
pneumoniae strains lack all the proteins in the tryptophan biosynthetic pathway. 
Therefore studies have shown that human C.pneumoniae strains are quite sensitive to 
interferon-gamma when cultured in human cells and the subsequent persistent 
phenotype can be reversed by adding back tryptophan (Beatty et al., 1994c; Hogan et 
al., 2004a). Thus host and tissue adaptations have selected for differential conservation 
of tryptophan biosynthesis within the genus Chlamydia. However, tryptophan-based 
determination of host and tissue specificity has not been well explored in C. 
pneumoniae. 
 
C. pneumoniae also appears to have unique arginine related adaptations. This species 
has a functional arginine responsive transcriptional repressor (Schaumburg and Tan, 
2006), arginine decarboxylase and arginine-agmatine antiporter (Giles and Graham, 
2007). In addition, excess exogenous arginine causes significant growth inhibition in 
vitro (Al-Younes et al., 2006a). The ability to uptake and degrade arginine is mostly 
likely a means of protection against the host cell pathogen oxidative attack compound 
nitric oxide (NO) (Giles and Graham, 2007). Immune signalling activates transcription 
of iNOS, which catabolises arginine to citrulline producing NO. Importantly, NO 
directly inhibits IDO activity via binding to the active site heme (Thomas et al., 2007). 
An in vitro study found that exogenous NO is able to inhibit IDO tryptophan 
catabolism, resulting in close to normal C. trachomatis L2 growth in epithelial cells (C. 
trachomatis L2 does not have a functional arginine decarboxylase (Giles et al., 2009)) 
(Roshick et al., 2006). Even with these adaptations to prevent NO attack, macrophages 
from iNOS-/- mice are more susceptible to C. pneumoniae infections in vitro 
(Rothfuchs et al., 2001; Rottenberg et al., 2000). Nonetheless, it is clear that C. 
pneumoniae can reduce host arginine levels, thereby reducing NO production and, 
paradoxically, allowing continued IDO activity, perhaps as a direct trigger for chronic 
or persistent growth. These arginine-based adaptations have not been extensively 
investigated but seem likely to also function in the shades of grey between acute and 
chronic disease states and tissue adaptations that exist within the ubiquitous C. 
pneumoniae. 
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2.12 CONCLUDING REMARKS 
Tryptophan availability and the ability to overcome active tryptophan depletion 
fundamentally define host and tissue tropism, and therefore pathogenicity, for 
Chlamydia. In this thesis, we discuss the hypothesis that sensing tryptophan 
bioavailability to trigger chronic growth or persistence has been selected for as a 
chronic disease advantage in human C. pneumoniae infections. We already know that 
ocular C. trachomatis are more sensitive to IFN-γ than the closely related genital strains 
and that they are more chronic in their growth and disease state. At the other end of the 
spectrum the ancestral animal C. pneumoniae strains appear to have been selected for a 
more aggressive, acute disease state. The versatile and highly prevalent human C. 
pneumoniae are clearly advantaged by this tryptophan-responsive chronic disease 
trigger, which may in fact be further adapted with tissue tropism and disease states 
within these strains.  
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3.1 GENERAL STOCKS AND SOLUTIONS 
3.1.1  Sucrose Phosphate Glutamate (SPG) 
SPG was prepared with 13.68 ml 0.5 M Na2HPO4, 6.32 ml 0.5 M NaH2PO4, 85.57g 
sucrose and 0.73 g L-glutamic acid in 1 L milli-Q H2O.The solution was pH adjusted to 
7.2 with NaOH and filter sterilised into smaller volumes. SPG was stored at 4˚C until 
required.  
3.1.2 Phosphate Buffered Saline (1x PBS) 
1x PBS was prepared with 8 g of NaCl, 0.2 g KCl, 1.44g Na2HPO4 and 0.24g KH2PO4 
in 1 L of milli-Q H2O.The pH was adjusted to 7.4 with HCL. The solution was sterilised 
by autoclaving at 121˚C for 15 minutes and was stored at room temperature until 
required. 
3.1.3 Cycloheximide 
Cycloheximide (Sigma Aldrich) was prepared by dissolving 20 mg in 20 ml of milli-Q 
H2O. The solution was filter sterilised into 0.5 ml aliquots and was stored at -20˚C until 
required.   
3.1.4 Trypsin ( 2x Trypsin) 
Trypsin was made as 2x stock by combining 10 ml of 10x trypsin (Sigma Aldrich) and 
40 ml 1x PBS.50 ml aliquots were stored at -20˚C until required. 
3.1.5 Streptomycin 
Streptomycin was made by dissolving 1g of streptomycin sulphate stock (Sigma 
Aldrich) in 100 ml of milli-Q H2O. The solution was filter sterilised into 5 ml aliquots 
and stored at -20˚C until required.  
3.1.6 Gentamycin 
500 µl of gentamycin (50 mg ml-1; Gibco) aliquots were stored at 4˚C until required. 
3.1.7 Heat inactivated Fetal calf serum (HI-FCS) 
Fetal calf serum (Lonza, Australia) was heat inactivated at 56 ˚C for 30 minutes and 25 
ml aliquots were stored at -20˚C. 
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3.1.8 Growth Media 
Dulbecco’s modified Eagle Medium (DMEM) (Invitrogen) was supplemented with 5% 
HI-FCS, 50 µg ml-1 gentamycin and 100 µg ml-1 streptomycin. The Roxwell Park 
Medical Institute (RPMI) 1640 culture medium (Invitrogen) was supplemented with 
10% HI-FCS and 100 µg ml-1 streptomycin. Media was stored at 4˚C.  
3.2 CELL CULTURE 
3.2.1 Cell Lines 
Cell lines used in this study were received from American Type Culture Collection 
(ATCC). Human bronchial epithelium BEAS-2B (ATCC CRL-9609) cells were grown 
in RPMI 1640 culture medium supplemented with 10% HI-FCS, 100 µg ml-1 
streptomycin at 37˚C and 5% CO2. HEp-2 (ATCC CCL-23) human epithelial cells and 
McCoy B (ATCC CRL-1696) murine fibroblast cells were grown in DMEM media 
supplemented with 5% HI-FCS, 50 µg ml-1 gentamycin and 100 µg ml-1 streptomycin at 
37˚C, 5% CO2. All the cells were periodically determined Mycoplasma spp. free by 
PCR. 
3.2.2 C. pneumoniae isolates 
The C. pneumoniae isolates used in this study included; C. pneumoniae AR39 (ATCC 
53592), a human pharyngeal isolate, AO3 an aortic isolate (ATCC VR-1452) from 
atheroma of a patient with coronary artery disease (Ramirez, 1996a), LPCoLN 
(Wardrop et al., 1999) a koala respiratory isolate and B21 a bandicoot ocular isolate 
(Kumar et al., 2007a). Isolates were routinely cultured in BEAS-2B cells. Confluent 
BEAS-2B cell monolayers were infected with C. pneumoniae inoculum at multiplicity 
of infection (MOI) of 1 in RPMI 1640 culture medium supplemented with 10% FCS 
and 100 µg ml-1 streptomycin. The infected monolayers were centrifuged at 1000 g for 
60 minutes at 25˚C and were incubated for 4 hours at 37˚C, 5% CO2. Media change was 
performed at 4 hours post infection by addition of fresh RPMI containing 1 µg ml-1 
cycloheximide and the infected monolayers were incubated for 72 hours at 37˚C, 5% 
CO2. Host cells were washed with 1 x PBS, trypsinized into suspension and pooled in 
RPMI medium. The cell suspension was centrifuged at 500 g for 5 minutes and the 
pellet was resuspended in 1x PBS. Cells were lysed (Ultrasonic Cell Disruptor XL, 
Microson, USA) and the host cell debris were pelleted at 900 g for 5 minutes. The 
supernatant were centrifuged using bench-top centrifuge at 18,000 × g for 30 mins. The 
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(chlamydial) pellet was resuspended in SPG and 100 µl aliquots were stored at -80˚C 
for future experiments. C. pneumoniae stocks were quantified according to the protocol 
described in 3.2.3.  
3.2.3 Determination of yield of inclusion forming units or viable infectious 
Chlamydia 
The infectious yield of C. pneumoniae was determined by counting of the inclusion 
forming units (IFU) ml-1 in BEAS-2B cells or HEp-2 cells or McCoy B cells as 
appropriate. Cultures were harvested in SPG and stored at -80˚C. Plates were thawed 
and probe sonicated for 60 seconds (Ultrasonic Cell Disruptor XL, Microson, USA). 
Confluent cells plated on coverslips were infected with serial dilution of the cell lysates. 
After 72 h PI, the cell monolayer was washed with PBS and fixed using 100% methanol 
for 10 mins. Chlamydial inclusions were stained with anti-LPS fluorescein 
isothiocyanate and counterstained with Evan’s blue to visualise host cells (Cell labs, 
Australia). Triplicate samples at appropriate serial dilutions were counted in 10 fields of 
view per dilution using Leica TCS SP5 confocal (FITC) labelled anti-Chlamydia 
lipopolysaccharide (anti-LPS) monoclonal antibody laser-scanning microscope (Leica 
Microsystems, Wetzlar, Germany). Images were prepared using the Leica Software 
Suite. Statistical analysis of viable infectious yield was conducted using GraphPad 
Prism (Version 7) for Windows (GraphPad Software, La Jolla California USA). 
GraphPad was also used to construct graphical images. 20 fields of view in total were 
counted from at least three independent cultures cultured onto separate coverslips in 
triplicate times for each condition, Statistical analysis was conducted by GraphPad, 
typically using Student’s two tailed t test (a minimum of n = 20 was used for each data 
point graphed in the provided datasets). Each dataset shown is representative of 
triplicate independent samples from one experiment, although these are consistent and 
representative of the observations made when independent repeats of each experiment 
were also conducted. Analysis of inclusion size was conducted using the Leica Software 
measurement tool to measure representative inclusions. Statistical analysis was 
conducted using GraphPad as above. 
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3.2.4 Confocal Microscopy 
C. pneumoniae infected cell monolayers cultured on coverslips were used for confocal 
laser scanning microscopy. At the indicated times the coverslip cultures were washed 
with PBS and were fixed with 100% methanol for 10 mins. Coverslips were stained 
with fluorescein isothiocyanate (FITC) labelled Chlamydia-specific anti-
lipopolysaccharide (anti-LPS) monoclonal antibody and counterstained with Evan’s 
blue to visualize hosts cells and were mounted on to slides in Prolong Gold (Invitrogen). 
Confocal images were obtained using Leica TCS SP5 confocal laser-scanning 
microscope (Leica Microsystems, Germany) with a 63x oil objective. Maximum 
excitation wavelength of 490 nm and mean emission wavelength of 530 nm was chosen 
from the provided software (Leica application suite for advanced fluorescence) for 
FITC fluorophore and images were processed for presentation using the Leica software 
suite. 
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4.2 ABSTRACT 
 
One of the most significant activities induced by interferon-gamma against intracellular 
pathogens is the induction of IDO (indoleamine 2, 3-dioxygenase) expression, which 
subsequently results in the depletion of tryptophan. We tested the hypothesis that human 
strains of Chlamydia pneumoniae are more sensitive to tryptophan limitation than 
animal C. pneumoniae strains. The human strains were significantly more sensitive to 
IFN-γ than the animal strains in a lung epithelia cell model (BEAS-2B), with exposure 
to 1 U ml-1 IFN-γ resulting in complete loss of viable yield of human strains, compared 
to the animal strains where reductions in viable progeny were around 3.5 - 4.0 log. 
Strikingly, the IFN-γ induced loss of viability was completely rescued by removal of the 
IFN-γ and addition of exogenous tryptophan for the human strains, but not the animal 
strains. In fact, a human heart strain was more capable of entering a non-infectious, 
viable persistent stage when exposed to IFN-γ and was also more effectively rescued, 
compared to a human respiratory strain. Exquisite susceptibility to IFN-γ, specifically 
due to tryptophan availability appears to be a core adaptation of the human C. 
pneumoniae strains, which may reflect the chronic nature of their infections in this host.  
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4.3 INTRODUCTION  
The presence of foreign agents and pathogens is detected by host cell pattern 
recognition receptors that trigger a cascade of immunological activities (Shimada et al., 
2012b). Interferon-gamma (IFN-γ) is one cytokine involved in this response that is 
particularly important for defence against intracellular pathogens such as Chlamydia. 
The mechanism of human IFN-γ activity against Chlamydia trachomatis has been 
demonstrated to be primarily if not completely via tryptophan depletion via the 
induction of indoleamine 2,3-dioxygenase  (Beatty et al., 1994b). Chlamydia is a highly 
successful intracellular pathogen and yet it is auxotrophic for tryptophan; consequently 
the starvation of this essential amino acid acts as a major cellular mechanism in 
eliminating this pathogen (reviewed in Hogan et al., 2004b) . Therefore, this mechanism 
has selected for niche specific chlamydial adaptations with tissue specificity of ocular 
versus genital C. trachomatis strains determined by differential tryptophan biosynthetic 
capabilities (Morrison, 2000; Nelson et al., 2007; Nelson et al., 2005). Specifically, C. 
trachomatis serovars that infect the genital tract have conserved, fully functional genes 
for the final step in the biosynthetic pathway for tryptophan synthesis from indole 
(Nelson et al., 2007; Nelson et al., 2005), which could be available in the genital tissue 
via local microbiota (Nelson et al., 2007; Nelson et al., 2005). Other members of the 
Chlamydiaceae have different levels of conservation of the tryptophan biosynthesis 
operon. For example, Chlamydia (C.) caviae are relatively resistant to IFN-γ, as they 
can synthesise tryptophan from intermediates in the host cell metabolic pathway, 
including indole, anthranilate, and kynurenine (Wood et al., 2004a). Chlamydia (C.) 
abortus by comparison, lacks the enzymes for tryptophan synthesis and hence is 
sensitive to IFN-γ in ovine cells, however, this can be restored by adding exogenous 
tryptophan (Brown et al., 2001). The animal strain Chlamydia (C.) muridarum (closely 
related to C. trachomatis) is resistant to mouse IFN-γ in mouse cells (McCoy B) while 
C. trachomatis is sensitive in these mouse cells. This is because the IFN-γ defence 
pathway is different between mouse and human cells; murine IFN-γ does not induce 
IDO in epithelia but instead induces p47 GTPases and the murine Chlamydia may be 
able to counteract this activity, possibly by a cytotoxin found on the genomes only of 
this chlamydial species (Nelson et al., 2007). Thus, host and tissue adaptations have 
selected for differential conservation of tryptophan biosynthesis within the genus 
Chlamydia. 
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Tryptophan-based determination of host and tissue specificity has not been well 
explored in Chlamydia (C.) pneumoniae. C. pneumoniae is unique within the 
Chlamydiaceae family as this organism is thought to have been relatively recently 
acquired from animal sources (Myers et al., 2009). C. pneumoniae has been identified 
in numerous animals including koalas, snakes, horses and other mammals (Berger et al., 
1999; Bodetti et al., 2002a; Bodetti et al., 2002c; Bodetti and Timms, 2000; Bodetti et 
al., 2003). Recently, comparative genomics suggested that the koala respiratory isolate, 
C. pneumoniae LPCoLN, is potentially ancestral to some human C. pneumoniae isolates 
(Mitchell et al., 2010a; Mitchell et al., 2010c; Myers et al., 2009). All of the C. 
pneumoniae strains have a high level of genome conservation and do not have any 
tryptophan biosynthesis genes, although they do possess a copy of a functional aromatic 
amino acid hydroxylase (Abromaitis et al., 2009; Mitchell et al., 2010a). The copy 
numbers of the tyrP (tryptophan/tyrosine permease) also varies between the C. 
pneumoniae human isolates; C. pneumoniae AR39 and CWL029 have two copies, 
whereas TW183 and J138 have one copy (Gieffers et al., 2003a; Kalman et al., 1999a; 
Read et al., 2000a). LPCoLN has a single copy of tyrP, which has unique SNPs 
compared to the other C. pneumoniae strains, leading to four amino acid changes in the 
coding sequence (Mitchell et al., 2010a). In addition, C. pneumoniae (Kajaani 6 and 
CWL-029 isolates) also encodes arginine decarboxylase and arginine-agmatine 
antiporter proteins which catalyse L-arginine uptake, decarboxylation and the excretion 
of agmatine from the cell (Giles and Graham, 2007). These arginine related adaptions 
could have functional advantages to C. pneumoniae such as, maintaining pH 
homeostasis during unknown acidic encounters or inhibiting host cell polyamine 
biosynthesis, resulting in the reduction of  host cell proliferation or blocking nitric oxide 
(NO) synthesis by reducing the arginine concentrations in the host cell (Giles et al., 
2009). Even with these adaptations, the growth of the human C. pneumoniae respiratory 
isolate (CWL-029) was shown to be inhibited in vitro by the addition exogenous 
arginine (Al-Younes et al., 2006b). 
There is evidence that the human strains of C. pneumoniae are highly sensitive to IFN-γ 
induced tryptophan depletion, and there appears to be differences in this sensitivity 
(reviewed in Huston et al., 2014). The human C. pneumoniae respiratory isolates (BAL-
16 and BAL-37) have been reported to show sensitivity at 100 U ml-1 of IFN-γ and the 
coronary isolates (AO3 and CV-6) have been shown to exhibit sensitivity at 50 and 250 
 Chapter 4: Increased sensitivity to tryptophan availability is a positive adaptation by the human strains of Chlamydia 
pneumoniae 75 
U ml-1 IFN-γ respectively in human epithelial cells (Bellmann-Weiler et al., 2010; 
Byrne et al., 1986a; Byrne et al., 2001; Mehta et al., 1998; Pantoja et al., 2000b, 2001). 
Given that tryptophan has already been demonstrated to be a major factor in niche 
adaptation within the chlamydial family, and that the human strains of C. pneumoniae 
have significant genome variation compared to the animal strains, we aimed to 
investigate the hypothesis that increased sensitivity to tryptophan availability is a human 
host specific adaptation of C. pneumoniae. 
4.4 MATERIALS AND METHODS 
4.4.1 C. pneumoniae cell culture conditions and treatments    
All experiments were conducted at multiplicity of infection (MOI) of 0.1 or 1 as 
indicated (Fig 4.1). The BEAS-2B C. pneumoniae cultures were conducted in RPMI 
1640 culture medium (Invitrogen) supplemented with 10% FCS (Invitrogen, Australia), 
100 µg ml-1 streptomycin at 37˚C and 5% CO2. For C. pneumoniae experiments in HEp-
2 and McCoy cells (McCoy B) (sourced from the ATCC) Dulbecco’s modified Eagle 
Medium (DMEM) (Invitrogen) was supplemented with 5% FCS, 50 µg ml-1 gentamycin 
and 100 µg ml-1 streptomycin at 37˚C, 5% CO2. The experimental details were the same 
for all the three cell models and are described as follows. Cells were seeded in 48 well 
culture plates in presence of 0.01 to 2.5 U ml-1 human IFN-γ (Sigma, Australia) for 24 
h. After infection with C. pneumoniae strains, these treatments were replenished every 
24 h and the infectious yield, inclusion morphology, and % infectivity was measured at 
72 h PI. Tryptophan rescue experiments were conducted by pre-treatment from -24 h to 
48 h PI (0.1 or 1 U ml-1 human IFN-γ and 25 or 50 U ml-1 murine IFN-γ (Peprotech, 
USA)) and this was removed by media washes (3X) at 48 h PI and the cultures were 
replaced with fresh media supplemented with 200 µg mL-1 L-tryptophan (SigmaAldrich, 
Australia). Tryptophan-depleted media experiments were supplemented with either 
increasing concentrations of exogenous L-tryptophan (1-75 µg mL-1) or 5 -
fluorotryptophan (5-50 mg l-1) after infection (L-tryptophan and 5 -fluorotryptophan 
stocks were prepared by dissolving in 1 x PBS). IDO1 inhibition experiments were 
conducted using 0.8 mM 1-MT (L-1-methytryptophan) (Sigma, Australia). 15 ml of 20 
mM 1-MT stock solution was prepared by dissolving in 12 ml ddH2O with drop wise 
addition of 1 M NaOH until the compound dissolved completely and the pH was 
subsequently adjusted to 7.4 with 1 M HCL (Qian et al., 2009). Kynurenine pathway 
metabolites (stocks were prepared in 1 x PBS ) were added to cultures at the following 
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concentrations: 0.1 mM L-kynurenine, 3-hydroxy-DL-kynurenine, indole 
(SigmaAldrich, Australia) and 0.1 mM 5-bromo-N-(carboxymethyl) anthranilic acid 
(Santa Cruz Biotechnology, USA). In all culture experiments the indicated supplements 
were replenished every 24 h. Control cultures with no IFN-γ (media equivalent 
volumes) and/or controls (media or relevant solvents) were included in all the 
experiments (Fig 4.1). 
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Figure 4.1 Flow chart of experimental plans used in this chapter.  
The experiments were performed using C. pneumoniae AR39, AO3, LPCoLN and B21 isolates unless 
otherwise stated. Experimental actions performed at each time point are indicated in the relevant 
experiment (A) Experimental conditions to assess the effects of different concentrations of human IFN-γ 
in C. pneumoniae infected BEAS-2B and Hep-2 cells or after murine IFN-γ treatment in C. pneumoniae 
infected McCoy B cells. (B) Experimental conditions to determine if tryptophan depletion was 
responsible for human or murine IFN-γ mediated reductions in C. pneumoniae isolates by the addition of 
exogenous L-tryptophan in BEAS-2b or McCoy B cells (C) Experimental conditions to inhibit IDO1 
enzyme by using 1-L-methyl-tryptophan (1 -MT) inhibitor) in IFN-γ treated C. pneumoniae infected 
BEAS-2B cells. (D) Experimental conditions to investigate the role of IDO1 downstream metabolites (L-
kynurenine, 3-hydroxy-DL-kynurenine, indole, anthranilic acid) in IFN-γ and 1-L-methyl-tryptophan 
treated C. pneumoniae infected BEAS-2B cells. (E) Experimental condition to investigate the role of 
IDO1 downstream metabolites (L-kynurenine, 3-hydroxy-DL-kynurenine, indole, anthranilic acid) in 
IFN-γ treated C. pneumoniae infected BEAS-2B cells. (F) Experimental conditions to investigate the 
sensitivity between C. pneumoniae isolates to available exogenous L- tryptophan (L-Trp) at different 
concentrations in BEAS-2B cells cultured in tryptophan depleted media was performed and in a separate 
parallel experiment investigation of the role of C. pneumoniae isolates in the manipulation of host 
tryptophan trafficking pathways was assessed by the addition of L-tryptophan analogue 5-flourotrytophan 
(5F-trp) in BEAS-2B cells cultured in tryptophan depleted media. (G) Experimental conditions to assess 
the production of nitric oxide after IFN-γ exposure in C. pneumoniae infected BEAS-2B cells. 
4.4.2 Western blot analysis 
 Mock infected cells and C. pneumoniae infected cell cultures in flasks were harvested 
at 48 or 72 h PI and washed with PBS. Cells were then lysed in lysis buffer (150 mM 
sodium chloride, 1.0% NP - 40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate, 50 mM Tris, pH 8.0) and protease inhibitor cocktail (Sigma) and were 
analysed by SDS-PAGE electrophoresis followed by immunoblotting using a standard 
protocol. The blots were probed with an anti-IDO1 mouse primary monoclonal antibody 
(Millipore, Australia) or anti-iNOS rabbit primary polyclonal antibody followed by 
horseradish peroxidise (HRP)-conjugated anti-mouse or anti-rabbit secondary antibody. 
Duplicate blots were probed with anti β-actin polyclonal antibody (Abcam, Australia) 
followed by an anti-rabbit secondary antibody conjugated to HRP. The reaction was 
developed with Pierce ECL Western Blotting Substrate (Thermo Scientific, Australia). 
Densitometric analysis of IDO1 protein level was performed using the Image J program 
(NIH). Densitometry data from three separate blots (from three independent culture 
experiments) were used. The IDO1 band intensity on each blot was normalised to the 
IFN-γ induced uninfected controls. Statistical analysis and graph was conducted using 
GraphPad Prism. 
4.4.3 Determination of tryptophan levels by reverse phase HPLC 
Tryptophan levels were measured in C. pneumoniae infected IFN-γ culture supernatants 
at 72 h PI. For comparability, both cells and media supernatant were processed using the 
same extraction protocol. At the indicated time point, 395µl of each cell culture 
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supernatant was added to 1.6 ml of ice cold HPLC-grade methanol, sonicated on ice 
(Ultrasonic Cell Disruptor XL, Microson, USA) and centrifuged at 1000 × g for 5 mins 
at 4°C.  The resulting supernatant was then lyophilised and the metabolite “pellet” was 
redissolved in 30 µl of ddH2O. To normalise for unlikely discrepancies in injection 
volume, 1:1 dilutions of processed samples with internal standard were performed. In 
brief, derivatised amino acids were analysed by RP-HPLC. Derivatisation was 
performed in a high-performance autosampler (Agilent HiP-ALS SL, G1367C). 0.5 uL 
of sample containing 250 uM of internal standards, sarcosine and 2-aminobutanoic acid, 
was added into 2.5 uL of borate buffer (0.4 N, pH 10.2, Agilent PN: 5061-3339), mixed 
and incubated for 20 s at 4oC. 1 uL of OPA reagent (10 mg o-pthalaldehyde/mL in 3-
mercaptopropionic acid, Agilent PN: 5061-3335) was then added to initially derivatise 
primary amino acids. The reaction was mixed and incubated for 20 s at 4oC. Then to 
derivatised other amino acids, 0.4 uL of FMOC reagent (2.5 mg 9-fluorenylmethyl 
chloroformate /mL in acetonitrile, Agilent PN:5061-3337) was added, mixed and 
incubated for 20 s at 4oC. 45.6 uL of Buffer A (40 mM Na2HPO4, 0.02% NaN3, pH 7) 
was added to lower the pH of the reaction prior to injecting the 50 uL reaction onto an 
Agilent Zorbax Extend C-18 column (3.5 um, 4.6 x 150 mm, Agilent PN: 763953-902) 
with a guard column (SecurityGuard Gemini C18, Phenomenex PN: AJO-7597). 
Column temperature was kept at 37oC in a thermostatted column compartment (Agilent 
TCC, G1316B). Chromatography was performed using an Agilent 1200-SL HPLC 
system, equipped with an active seal wash and a degasser (Agilent Degasser, G1379B). 
The HPLC gradient was 2-45% B from 0-18 min, 50-60% B from 18.1-20 min, 100% B 
from 20.1-24 min, and 2% B from 24.1-27 min – using a binary pump (Agilent Bin 
Pump SL, G1312B).  Buffer B was 45% acetonitrile, 45% methanol and 10% water. 
Flow rate was 2 mL/min. Derivatised amino acids were monitored using a fluorescence 
detector (Agilent FLD, G1321A). OPA-derivatised amino acids were monitored at 340ex 
and 450em nm from 1-18 min, and FMOC-derivatised amino acids at 266ex and 305em 
nm from 18-27 min. Chromatograms were integrated using ChemStation. The 
concentration of tryptophan (and other amino acids) in samples was quantified by 
comparing the retention time and ratio of the sample peak area to that of the peaks of a 
standard curve, as described in (Dietmair et al., 2010) with the following modifications. 
In brief, derivatised amino acids were analysed by RP-HPLC. 0.5 µl of sample 
containing 250 µM of internal standards, sarcosine and 2-aminobutanoic acid, was 
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added into 2.5 µl of borate buffer (0.4 N, pH 10.2), mixed and incubated (20s at 4oC). 
1µl of OPA reagent (10 mg o-phthalaldehyde/ml in 3-mercaptopropionic acid) was then 
added to derivatise primary amino acids. Then 0.4 µl of FMOC reagent (2.5 mg 9-
fluorenylmethyl chloroformate /mL in acetonitrile) was added to derivatise other amino 
acids. 45.6 µl of Buffer A (40 mM Na2HPO4, 0.02% NaN3, pH 7) was added to lower 
the pH of the reaction prior to injecting the 50 µl reaction onto an Agilent Zorbax 
Extend C-18 column (3.5 um, 4.6 x 150 mm, Agilent) with a guard column 
(SecurityGuard Gemini C18, Phenomenex). Column temperature was maintained at 
37oC. The HPLC gradient was 2-45% B from 0-18 min, 50-60% B from 18.1-20 min, 
100% B from 20.1-24 min, and 2% B from 24.1-27 min.  Buffer B was 45% 
acetonitrile, 45% methanol and 10% water. Flow rate was 2 ml/min. Derivatised amino 
acids were monitored using a fluorescence detector, from 1-18 min for OPA-derivatives 
and from 18-277 min for FMOC-derivatives. Results were analysed using a Student’s t 
test from a minimum of n=3 samples. The experiment was repeated on a separate 
occasion and the results were consistent with those presented here. 
 
4.4.4 Assessment of Nitric oxide production by Greiss reagent 
Nitric oxide levels (as nitrite, one of the stable primary breakdown product of nitric 
oxide) was measured in C. pneumoniae (Human AR39 or animal LPCoLN isolates) 
infected BEAS-2B cells at 48 h PI under the following conditions with IFN-γ, 1-MT, L-
tryptophan, L-arginine or combinations of 1-MT with IFN-γ and/or L-tryptophan and/or 
L-arginine and positive control of IFN-γ exposed BEAS-2B cells stimulated with LPS 
was also included. Briefly, 50μl of the supernatant was mixed with 50 μl of each greiss 
reagent (1 % sulphanilamide, 0.1% naphthylethylene diamine dihydrochloride, 2.5% 
phosphoric acid; Promega, Australia) and the absorbance was measured at 550 nm 
wavelength with a microplate spectrophotometer. The OD 550 was converted to nitrite 
concentrations using a nitrite standard curve. Results represent µM nitrite 
concentrations and are the mean ± SD of two independent experiments. 
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4.5  RESULTS 
4.5.1 Differential susceptibility of human and animal C. pneumoniae strains to 
IFN-γ during culture in BEAS-2B lung epithelia cells 
The impact of IFN-γ treatment of human epithelial cells on the growth characteristics of 
the animal C. pneumoniae isolates (koala - LPCoLN) and (bandicoot - B21) and human 
respiratory (AR39) and aortic (AO3) isolates was examined. These experiments were 
conducted in BEAS-2B cells, as this immortalised lung epithelial cell line has been 
demonstrated to possess many properties consistent with primary lung epithelial 
cultures (Kinnula et al., 1994). The BEAS-2B cells were pre-exposed to various 
concentrations (0.01 U ml-1 to 2.5 U ml-1) of IFN-γ for 24 h prior to infection and the 
cytokine was replenished (every 24 h) throughout the culture until completion of the 
developmental cycle for C. pneumoniae (72 h PI). Infections were conducted at two 
different multiplicity of infection levels (MOI) (0.1 and 1 for each isolate). We first 
examined the impact of IFN-γ treatment on the ability of the C. pneumoniae strains to 
generate infectious progeny (i.e. complete their developmental cycle) by re-culturing the 
infections on fresh cell monolayers (Fig. 4.2 ). The human isolates were considerably 
more sensitive to IFN-γ treatment than the animal isolates, with 0.1 U ml-1 IFN-γ 
resulting in dramatic reductions in infections yield; 2 log less IFU ml-1 compared to 
untreated controls for AR39 (MOI 0.1) and 5.5 log less IFU ml-1 for AO3 (MOI 0.1) 
compared to controls conditions (p<0.001) (Fig. 4.2 A. and 3.2B.). By comparison, this 
concentration of IFN-γ resulted in only relatively minor reductions for both LPCoLN 
and B21 isolates, with 1.5 log fewer IFU ml-1 after culture with 0.1 U ml-1 IFN-γ (MOI 
0.1) compared to the untreated control for LPCoLN, and 2 log fewer IFU ml-1 for the 
bandicoot B21 isolate (MOI 0.1) (Fig. 4.2 C. and 3.2D.). The human isolates showed no 
detectable infectious progeny after treatment with 2.5 U ml-1 IFN-γ, whilst infectious 
progeny were still detected for the animal isolates at this concentration (Fig. 4.2.). The 
animal strains had higher yields of infectious progeny under these conditions and 
therefore, in order to allow comparison between the isolates we determined the fold 
change relative to untreated controls for 0.1, 1, 2.5 U IFN-γ and statistically analysed 
the data to determine if these are different for each isolate compared to AR39 at 0.1 U 
IFN-γ (Table 4.1). There was a significant difference between AR39 and A03 (p<0.05), 
however, this was not as marked as the difference between AR39 and the animal 
isolates (p<0.001) (Table 4.1). 
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Figure 4.2 IFN-γ treatment of BEAS-2B C. pneumoniae cultures is more detrimental for production 
of infectious progeny for the human strains than the animal strains.  
The figure shows the inclusion forming units of C. pneumoniae generated from IFN-γ treated BEAS-2B 
cultures following passage, at 10-fold serial dilutions, into new BEAS-2B monolayers. The inclusion 
forming units ml-1 are indicated on the Y axis and then different IFN-γ treatment conditions are indicated 
by the grey scale shading (legend to right). # indicates that no inclusion forming units were detected. The 
two different multiplicity of infection levels (MOI) are indicated on the x-axis. Statistics were conducted 
using Student’s two tailed t test relative to untreated controls (n = 20). (A) C. pneumoniae AR39; (B) C. 
pneumoniae AO3; (C) C. pneumoniae LPCoLN and (D) C. pneumoniae B21. The cultures had significant 
reductions in infectious yield when treated with IFN-γ at all concentrations greater than 0.01 U ml-1 for 
both multiplicity of infection tested (p<0.001) 
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Table 4.1 Fold change data of inclusion forming units relative to the control for each isolate 
 0.1 U IFN-γ 1 U IFN-γ 2.5 U IFN-γ 
AR39 0.0037 (0.0008) # 0 # 0 
AO3 3.21e-005 (9.6e-6)* # 0 # 0 
LPCoLN 0.017 (0.0027)*** 1.89e-004 (2.6e-5) 3.04e-007 (8.9e-8) 
B21 0.011 (0.0017)*** 0.0008575 (1.1e-4) 3.59e-007 (1.1 e-7) 
# 0 indicates no infectious progeny detected under these conditions so fold change data not analysed. Standard error 
of the mean are indicated in parenthesis. Tukey’s multiple comparison test was used to test for significant differences 
between these fold change data by comparing each isolates data to AR39. * p<0.05, *** p<0.001 
 
 
4.5.2 IFN-γ treatment of C. pneumoniae cultures in BEAS-2B cells induces 
persistence morphology at lower doses for the human strains than for the 
animal strains. 
IFN-γ is known to induce the formation of persistent Chlamydia (viable but non-
infectious), which are characterised by the presence of large chlamydial cell 
morphology, and fewer inclusions that are smaller in size (Pantoja et al., 2001). 
Therefore, the cultures were examined by immunocytochemistry and confocal 
microscopy at 72 h PI to look for evidence of persistence morphology. Representative 
images of the cultures from treatment and control conditions for each isolate are shown 
in Fig. 4.3. The human C. pneumoniae strains had inclusion and cellular morphologies 
consistent with persistence under all conditions where reduced infectious progeny was 
observed in Fig. 4.2.; smaller inclusions with fewer larger circular cell types present in 
each inclusion. In contrast, for the animal isolates, even at 1 U ml-1 IFN-γ where 3.5-4.5 
log reduction in infectious progeny was observed, we observed (mainly) normal 
inclusion morphology and were not able to detect inclusions with morphologies 
consistent with persistence. At a concentration of 2.5 U ml-1 IFN-γ where dramatic 
reductions in yield of infectious progeny were observed for the animal isolates, there 
were still predominantly ‘normal’ inclusions visible in the cultures, although there was 
also a small proportion of inclusions present that were consistent with persistent 
morphology. 
We quantified these observations by measuring the size of 20 inclusions directly in the 
IFN-γ treated cultures. The human AR39 inclusions were significantly (p< 0.0001) 
smaller during IFN-γ treatment conditions (1 U ml-1 IFN-γ) with a mean of 2.89 µm (± 
 84Chapter 4: Increased sensitivity to tryptophan availability is a positive adaptation by the human strains of 
Chlamydia pneumoniae 
0.66 standard deviation (SD)) compared to 9.37 µm (± 1.64 SD) in the control (no IFN-
γ) (Table 4.2). A similar reduction of the inclusion size during IFN-γ treatment was also 
observed for the human AO3 isolate at 2.48 µm (± 0.99 SD) with 1 U ml-1 IFN-γ 
compared to 7.99 µm (± 1.39 SD) in the control conditions. By comparison, no decrease 
in inclusion size was detected for either of the animal isolates Table 4.2). The koala 
isolate LPCoLN had inclusions that were 21.60 µm (± 4.84 SD) when cultured in the 
presence of 1 U ml-1 IFN-γ compared to 21.2 µm (± 4.58 SD) in the untreated controls 
(Table 4.2). 
In these experiments the IFN-γ was added 24 h prior to the infection, so that tryptophan 
would have been depleted from the cultures at the time of infection. Therefore, in order 
to determine if the loss of infectious progeny identified in Fig. 4.2., was a consequence 
of  the failure to successfully develop and maintain a detectable inclusion vacuole or a 
consequence of the development of persistence, the percentage of cells infected at 72 h 
PI during IFN-γ treatment was counted (Table 4.3). There were some reductions in 
percent infectivity for the human isolates (approximately half the cells were infected at 
1 U ml-1 IFN-γ compared to the control), however, not enough to adequately explain the 
complete loss of inclusion forming units. The animal isolates had only minor reductions 
in the percent infectivity under the IFN-γ treatment conditions, with only a quarter of 
the reductions in percent infected cells at 1 U ml-1 IFN-γ, whereas the yield of infectious 
progeny was found to be 3.5-4.5 log less (Table 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4: Increased sensitivity to tryptophan availability is a positive adaptation by the human strains of Chlamydia 
pneumoniae 85 
 
Figure 4.3 IFN-γ treatment of C. pneumoniae cultures in BEAS-2B cells induces persistence 
morphology at lower doses for the human strains than the animal strains.  
The figure shows representative confocal microscopy images of BEAS-2B C. pneumoniae cultures (MOI 
0.1) at 72 h PI at either 0 (control), 0.1, 1, and 2.5 U ml-1 IFN-γ. The scale bar in the bottom right of each 
image represents 10 µm. A mixture of morphologies were present in the animal isolates at 2.5 U ml-1 
IFN-γ, therefore the final column is a composite of four representative images for this condition. 
Representative images of BEAS-2B C. pneumoniae (A) C. pneumoniae AR39; (B) C. pneumoniae AO3; 
(C) C. pneumoniae LPCoLN and (D) C. pneumoniae B21 cultures from control, 0.1, 1, and 2.5 U ml-1 
IFN-γ. 
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Table 4.2   Inclusion size measurements at 72 h PI are indicated. 
Strain No treatment 0.1 IFN γ 1 IFN γ 2.5 IFN γ 
Human AR39 9.37 ± 1.64 3.07 ± 0.76*** 2.89 ± 0.66*** 2.63 ± 0.57*** 
Human AO3 7.99 ± 1.39 2.67 ± 0.87*** 2.48 ± 0.99*** 1.53 ± 0.42*** 
Koala LPCoLN 21.21 ± 4.58 21.53 ± 4.77 21.6 ± 4.84 14.30 ± 5.90*** 
Bandicoot B21 24.86 ± 5.00 22.52 ± 5.53 24.74 ± 4.02 14.29 ± 7.32*** 
The inclusion sizes were measured under each condition from (two independent experiments) and the table shows the mean ± SD (n= 20), *** p< 0.0001 compared to the control culture (no 
treatments). Statistical analyses were performed using Student’s two tailed t test. 
 
 
 
Table 4.3 Percent of cells infected in representative fields of view for each strain during cell culture in the presence and absence of IFN-γ 
 No IFN-γ 0.1 IFN-γ 1 IFN-γ 2.5 IFN-γ (U ml-1) 
Human AR39 8.66 ± 3.53 7.50 ± 4.28 4.83 ± 2.54*** 4.60 ± 2.25*** 
Human AO3 4.77 ± 3.97 2.14 ± 0.80 ** 2.28 ± 0.59 ** 1.28 ± 0.83*** 
Koala LPCoLN 8.39 ± 7.29 8.20 ± 4.67 6.28 ± 2.51 3.28 ± 1.83** 
Bandicoot B21 7.24 ± 3.58 6.16 ± 2.69 6.06 ± 1.98 3.72 ± 1.49*** 
Data are mean ± SD (n = 20). Statistics were conducted using Student’s two tailed t test compared to the control culture (no treatment) (n = 20; ** p < 0.01, *** p < 0.001).
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4.5.3 C. pneumoniae IFN-γ sensitivity in HEp-2 cells is similar to that found in 
BEAS-2B cells 
This is the first reported use of BEAS-2B cells to examine the IFN-γ persistence model 
for Chlamydia, though they have been previously reported to be able to be infected by 
C. pneumoniae (Jahn et al., 2000; Kru¨ll et al., 2006). In order to confirm that the 
comparatively low dose of IFN-γ needed to reduce the infectious progeny observed here 
is not a feature specific to these cells, we repeated these experiments in the commonly 
used cell line HEp-2. We observed similar impacts on the production of infectious 
progeny production for all four isolates (MOI 0.1) for the same doses of IFN-γ when 
HEp-2 cells were used (Fig. 4.4). The human isolates both had a complete loss of 
inclusion forming units at 1 U IFN-γ ml-1 and above, whereas the animal isolates had a 
three log loss of viability under the same conditions (Fig. 4.4). 
 
 
Figure 4.4 Infectious progeny from HEp-2 C. pneumoniae cultures treated with IFN-γ 
(A) C. pneumoniae AR39, the cultures had significant reductions in infectious yield when treated with 
IFN-γ at all concentrations greater than 0.1 U ml-1 for 0.1 multiplicity of infection (p<0.001), (B) C. 
pneumoniae AO3, the cultures had significant reductions in infectious yield when treated with IFN-γ at all 
concentrations greater than 0.01 U ml-1 for the multiplicity of infection of 0.1 (p<0.001), (C) C. 
pneumoniae LPCoLN, the cultures had significant reductions in infectious yield when treated with IFN-γ 
at all concentrations greater than 0.1 U ml-1 for 0.1 multiplicity of infection (p<0.001), (D) C. pneumoniae 
B21, the cultures had significant reductions in infectious yield when treated with IFN-γ at all 
concentrations greater than 0.1 U ml-1 for 0.1 multiplicity of infection (p<0.001). 
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4.5.4 IFN-γ treatment from a different supplier (Roche) also show similar trends in 
the infectious progeny production after IFN-γ treatments in BEAS-2B cells 
Since our results demonstrated reduced infectious progeny production in C. pneumoniae 
isolates at low doses of IFN-γ compared to the previous literature, the sensitivity of C. 
pneumoniae isolates to IFN-γ between the two separate suppliers of IFN-γ, Roche, 
Australia and Sigma, Australia (IFN-γ supplier used in this study) were tested. BEAS-
2B cells were infected with human AR39 and animal LPCoLN isolates (MOI 1) and 
were pre-treated (24 h prior to infection) with the previously reported range of IFN-γ 
(50 or 100 U ml-1) from both the suppliers. IFN-γ was, replenished every 24 h in C. 
pneumoniae infected cultures, until 72 h PI. Both C. pneumoniae isolates showed dose 
dependant variations between suppliers, with IFN-γ from Sigma resulting in complete 
loss of infectious progeny production and IFN-γ from Roche (Fig. 4.5) showing similar 
impacts on the production of infectious progeny, as observed in our previous 
experiments using low concentrations of IFN-γ from Sigma (Fig. 4.2 ). Human isolate 
AR39 demonstrated an increased sensitivity to IFN-γ, with 50 U ml-1 IFN-γ (Roche) 
resulting in 3 log fewer IFU ml-1 and 100 U ml-1 of IFN-γ (Roche) showing 4 log less 
IFU ml-1 compared to untreated controls for AR39 (Fig. 4.5A). However, the animal 
LPCoLN isolate showed only minor reductions (1 log) after 50 or 100 U ml-1 IFN-γ 
(Roche) treatment (Fig. 4.5B). After IFN-γ treatment, only the human isolate and not 
the animal isolate, demonstrated the presence of persistent chlamydial morphology, a 
finding which is consistent with our previous observations (Fig. 4.6). Thus, the two 
IFN-γ suppliers showed similar trends in the sensitivity between the human and the 
animal C. pneumoniae isolates; however the effects occurred at different concentrations. 
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Figure 4.5 C. pneumoniae isolates show similar trends in the infectious progeny production after 
IFN-γ treatments from a different supplier (Roche) was used.  
The inclusion forming units ml-1 is indicated on the Y axis and then different IFN-γ treatment conditions 
are indicated by the grey scale shading (key included on the right of the figure). Data are mean ± SEM 
with n = 20. ***p < 0.001, Student’s two tailed t test.  (A) The inclusion forming units ml-1 of C. 
pneumoniae AR39 from BEAS-2B IFN-γ treated cultures at 72 h PI is shown on the graph. (B) The 
inclusion forming units ml-1 of C. pneumoniae LPCoLN from BEAS-2B IFN-γ treated cultures at 72 h PI 
is shown on the graph. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 IFN-γ treatment from a different supplier (Roche) also induces persistence morphology 
in the human isolate and not the animal isolate. 
The figure shows representative confocal microscopy images of BEAS-2B C. pneumoniae cultures (MOI 
1) at 72 h PI at either 0 (control), 50 and 100 U ml-1 IFN-γ. Scale bar: 10 µm. Representative images of 
(A) C. pneumoniae AR39 and (B) C. pneumoniae LPCoLN from control, 50 and 100 U ml-1 IFN-γ  in 
BEAS-2B cells. 
 
A 
B 
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4.5.5 IDO1 expression is not blocked by the Chlamydia, in IFN-γ treated BEAS-2B 
C. pneumoniae cultures 
 The established mechanism behind IFN-γ reduction of chlamydial infectious progeny 
production in human epithelial cells is via the induction of the expression of 
indoleamine 2, 3-dioxygenase 1 (IDO1) (Beatty et al., 1994b; Byrne et al., 1986b). 
However, we also know that Chlamydia are capable of prevention many of the cytokine 
induced signals in epithelial cells, one example being the binding of CP0236 to Akt1 
preventing NF-κb activation and IL-17 signalling inside infected cells (Wolf et al., 
2009a). Therefore, in order to confirm that IDO1 expression was induced in the BEAS-
2B cells by IFN-γ and that this expression was not modulated by the C. pneumoniae 
strains, western blots were conducted. As shown in Fig. 4.7A, the IDO1 protein was 
induced in BEAS-2B cells (not infected with Chlamydia) when IFN-γ was added. The 
IDO1 protein continued to be induced in the BEAS-2B cells following the infection of 
these cultures with C. pneumoniae (Fig. 4.7A). We conducted densitometry analysis of 
IDO1 band intensity from western blots for each of the isolates, relative to an internal 
host control (three independent biological experiments on separate westerns). This 
showed no significant differences in the levels of IDO1 induction (Fig. 4.7B). None of 
the  strains altered the IFN-γ induction of IDO1 in this model and therefore the 
differential susceptibilities do not relate to a modulation of IFN-γ signalling upstream of 
IDO1 protein induction. 
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Figure 4.7 The IDO1 protein is present in the IFN-γ treated C. pneumoniae BEAS-2B cultures. 
(A) Western blot for IDO1 protein in cell lysates of the IFN-γ treated BEAS-2B cultures. The culture and 
concentration of IFN-γ is indicated above each lane at the top of the figure. The size of relevant molecular 
weight markers are indicated to the right of the figure and the western blot band identity (i.e. IDO1 or β-
actin) are indicated to the left. (B) Graphical representation of densitometry analysis of IDO1 band 
intensity in each of the isolates relative to a host control included on each western from three independent 
western blots. 
 
4.5.6 Addition of exogenous tryptophan rescues the production of infectious 
progeny of IFN-γ treated BEAS-2B C. pneumoniae cultures 
In addition to the induction of IDO1, IFN-γ is a pleiotropic cytokine that has been 
shown to induce a large number of additional genes (~1000 gene transcripts) when 
added to human lung epithelial cells (Pawliczak et al., 2005). Therefore, we conducted 
tryptophan rescue experiments to determine if depletion of tryptophan was responsible 
for (all) the observed reduction of C. pneumoniae production of infectious progeny. We 
conducted this in a rescue format because in addition to attributing the loss of infectious 
progeny to tryptophan depletion, restoration of infectious yield is consistent with 
chlamydial persistence. Specifically, BEAS-2B cells were cultured in the presence of 
IFN-γ (0.1 or 1 U ml-1) from 24 h prior to infection with the C. pneumoniae strains 
(MOI 0.1), and then at 48 h PI, the IFN-γ containing media was removed from all 
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cultures and replaced with media containing 200 µg ml-1 tryptophan supplementation 
and no IFN-γ (‘rescued’). Controls that were not ‘rescued’ at 48 h PI but continued with 
IFN-γ conditions were included in this experiment. 48 h (i.e. 96 h PI total) after this 
‘rescue’ the cultures were harvested for measurement of infectious progeny. In a control 
set of experiments we confirmed that the expected reduced progeny at 48 h PI in the 
presence of IFN-γ was observed for each isolate (Fig. 4.8). We then measured the 
infectious progeny from the ‘rescued’ and control cultures (Fig. 4.9.). These 
experiments produced several major findings. Firstly, for the human strains, the addition 
of exogenous tryptophan (200 µg ml-1) substantially restored the progeny lost following 
0.1 U IFN-γ treatment (Fig. 4.9A. and 4.9B.). Even though there was no residual 
infectivity after treatment with 1 U of IFN-γ in the human strains, 103 to 105 log 
production of infectious progeny could be recovered when exogenous tryptophan was 
added, clearly suggesting that these cultures had viable but non-infectious forms present 
(i. e. persistent infections) (Fig. 4.9A.). The second major finding was the difference in 
sensitivity between the respiratory (AR39) and aortic (AO3) isolates. Following IFN-γ 
exposure, the infectivity for the heart isolate was reduced more than for the respiratory 
isolate (105 fold decrease versus 103 fold decrease respectively) and yet the recovery 
following addition of exogenous tryptophan was much greater for the heart isolate 
(recovery to 106 for the heart isolate versus recovery to 103 for the respiratory isolate) 
(Fig. 4.9B.). This indirectly suggests that for the heart isolate, exposure to IFN-γ more 
effectively causes it to transition to the persistent state, which is then more effectively 
recovered when tryptophan again becomes available. The third finding relates to the 
recoverability by the animal strains. Even though IFN-γ treatment caused a less severe 
decrease in infectivity for the animal strains compared to the human strains, the addition 
of exogenous tryptophan after 1 U IFN-γ treatment was not as effective at recovering 
this infectivity, compared to the result for the human A03 strain (Fig. 4.9 C. and D.), 
with only 3.5-4.5 log less infectious yield initially observed rescued by 2-3 logs 
respectively at 1 U ml-1 IFN-γ treatments). We also analysed these data using fold 
change and found that the fold change relative to untreated controls of the 1 U IFN-γ L-
tryptophan rescued cultures, supports our finding that the animal strains were not as 
effective as human strain AO3 at rescue (fold change data with standard error of the 
mean are: AR39: 0.0004 ±0.000005; AO3: 0.42 ±0.15; LPCoLN: 0.019 ±0.002; B21: 
0.0032 ±0.0003). 
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Figure 4.8 Infectious progeny production of IFN-γ treated cultures at 48 hours prior to 
commencement of tryptophan rescue experiments. 
The inclusion forming units ml-1 is indicated on the Y axis and then different IFN-γ treatment conditions 
are indicated by the grey scale shading (key included on the right of the figure). (A) The inclusion 
forming units ml-1 of C. pneumoniae AR39 from BEAS-2B IFN-γ treated cultures at 48 h PI is shown on 
the graph. (B) The inclusion forming units ml-1 of C. pneumoniae A03 from BEAS-2B IFN-γ treated 
cultures at 48 h PI is shown on the graph. (C) The inclusion forming units ml-1 of C. pneumoniae 
LPCoLN from BEAS-2B IFN-γ treated cultures at 48 h PI is shown on the graph. (D) The inclusion 
forming units ml-1 of C. pneumoniae B21 from BEAS-2B IFN-γ treated cultures at 48 h PI is shown on 
the graph. 
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Figure 4.9 Tryptophan rescued C. pneumoniae human strains from IFN-γ treated conditions and 
restored production of infectious yield more effectively than for the animal strains. 
The infectious yield (inclusion forming units) of C. pneumoniae strains from cultures are shown on the 
graphs. The BEAS-2B infected cultures were conducted on standard media (first bar, clear), 0.1 U ml-1 
IFN-γ (until 96 h PI, light grey bar), 0.1 U ml-1 IFN-γ until 48 h PI with replacement of tryptophan 
enriched media until 96 h PI (darker grey bar), 1 U ml-1 IFN-γ (next grey shade, or # that indicates lethal 
or no detectable inclusion forming units), 1 U ml-1 IFN-γ until 48 h PI with replacement of tryptophan 
enriched media until 96 h PI (darkest grey bar), (legend indicated at the right of the figure). Data are mean 
± SEM with n = 20. ***p < 0.001, Student’s two tailed t test. Significant rescue was observed for all 
strains from both IFN-γ treatment conditions, that is when 0.1 U ml-1 IFN-γ was compared to 0.1 U ml-1 
IFN-γ with L-trp  Rescue or when 1 U ml-1 IFN-γ was compared to 1 U ml-1  IFN-γ with L-trp  Rescue. 
(A) The infectious yield (IFU ml-1) of C. pneumoniae human strain AR39 from cultures harvested at 96 h 
PI (indicated on the x axis). (B) The infectious yield (IFU ml-1) of C. pneumoniae human strain AO3 from 
cultures harvested at 96 h PI. (C) The infectious yield (IFU ml-1) of C. pneumoniae animal strain 
LPCoLN from cultures harvested at 96 h PI. (D) The infectious yield (IFU ml-1) of C. pneumoniae animal 
strain B21 from cultures harvested at 96 h PI. 
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4.5.7 Human and animal C. pneumoniae isolates have different requirements for 
tryptophan 
Since tryptophan rescued C. pneumoniae human strains more effectively from IFN-γ 
treated conditions than the animal strains, the sensitivity between these isolates to 
available exogenous tryptophan was examined. BEAS-2B cells were infected in 
tryptophan deficient media at an MOI 0.5 with human AR39 or animal LPCoLN 
isolates and were supplemented with increasing concentrations of exogenous tryptophan 
(1 to 75 µg ml-1). A lower MOI 0.5 was chosen for this experiment in order to attempt 
to account for the relative differences in the growth yields between these strains. As 
shown in Fig. 4.10, the growth of the human isolate was considerably increased 
compared to the animal isolate following the addition of increasing levels of exogenous 
tryptophan. In human AR39 cultures, the addition of low concentrations (5µg ml-1) of 
tryptophan resulted in 0.5 log increase in infectious progeny production and  a further 1 
log increase was observed with moderate (15 µg ml-1) to high concentrations (75µg ml-
1) of exogenous tryptophan compared to the control (0 µg ml-1 L-trp) cultures (Fig. 
4.10A). However, the animal LPCoLN isolate showed no change in the infectious 
progeny production with 1 to 15 µg ml-1 of exogenous tryptophan addition and showed 
only a marginal increase in the production of infectious progeny after the addition of 75 
µg ml-1 of exogenous tryptophan in tryptophan depleted cultures (Fig. 4.10B). 
 
 
Figure 4.10 Increased sensitivity of human C. pneumoniae to available exogenous tryptophan. 
The figures represent the infectious yield of cultures (MOI 0.5) from tryptophan depleted media, where a 
range of exogenous L-tryptophan was supplemented after infection and were maintained until 72 h PI. 
The inclusion forming units ml-1 is indicated on the Y axis and then different treatment conditions are 
indicated by the grey scale shading (legend to right).  Data are mean ± SEM (n=20). Statistics were 
conducted using Student’s two tailed t test (***p < 0.001) relative to the control (0 µg ml-1 L-Trp). (A) The 
infectious yield of human AR39 at 72 h PI under each condition in BEAS-2B cells. (B) The infectious 
yield of animal LPCoLN at 72 h PI under each condition in BEAS-2B cells. 
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4.5.8 IDO1 inhibition does not restore the growth of animal C. pneumoniae isolates 
during IFN-γ treated human cell culture. 
The ability of exogenous tryptophan to rescue the production of infectious progeny of 
C. pneumoniae strains from IFN-γ treated cultures (or partially rescue in the case of the 
animal strains) further supports the hypothesis that IDO-induction is the major defence 
mechanism in this model. The IDO1 inhibitor 1-L-methyl-tryptophan (1-MT) was used 
to independently validate that IDO1 is critical for the IFN-γ impact. BEAS-2B cells 
were treated with IFN-γ, 1-MT, the 1-MT solvent (control), L-tryptophan, or 
combinations of 1-MT with IFN-γ and/or L-tryptophan, 24 h prior to and every 24 h 
during the cultures. At 72 h PI the cultures were harvested and the infectious yield was 
measured. The IFN-γ treated BEAS-2B human AR39 and AO3 cultures showed the 
expected reduction in infectious progeny consistent with our observations presented in 
the previous figures (Fig. 4.10A. and B.). The concurrent treatment of 1-MT with IFN-γ 
for AR39 and AO3 cultures resulted in an infectious yield similar to that observed with 
1-MT treatment alone and the other controls (i.e. equivalent to control growth). This 
result was consistent with the observations made in the tryptophan rescue experiment 
(Fig. 4.9.); that is the sensitivity of C. pneumoniae AR39 and AO3 to IFN-γ treatment of 
host cells was fully explained by tryptophan depletion, via IDO. Furthermore, enhanced 
growth (to a greater extent for AO3) was observed for the human isolates compared to 
controls when exogenous tryptophan was added (200 µg ml-1 L-tryptophan) with either 
1-MT, or both IFN-γ and 1-MT (Fig. 4.11A. and B.). These data combined demonstrate 
that the human C. pneumoniae strains are more sensitive to the host cell tryptophan 
availability and that the mechanism of IFN-γ defence against C. pneumoniae strain 
AR39 and AO3 in epithelial cells is via the IFN-γ-IDO1-Trp depletion mechanism. 
However, the findings for the 1-MT rescue of the IFN-γ treated cultures of the LPCoLN 
and B21 strains contrasted quite markedly with those for the human strains (Fig. 4.11C. 
and D.). The infectious yield of the animal strains were reduced approximately 3 or 4 
logs (0.1 or 1 U ml-1 IFN-γ respectively) by IFN-γ treatment (as consistent with the 
previous observations made in Fig. 4.2). However, in direct contrast to the finding for 
the human strains, the 1-MT treatment of the BEAS-2B infected animal strain cultures 
did not completely prevent the IFN-γ detrimental impact on the production of infectious 
progeny of these strains, with only 1.5 or 2.5 log higher yield in 1-MT with IFN-γ 
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conditions compared to corresponding IFN-γ conditions for LPCoLN and B21, 
respectively. This infectious yield was still 1 to 3 log lower than the infections yield  
observed in the control conditions, so for the animal strains IDO inhibition did not 
completely prevent the loss of infectious progeny from IFN-γ treatment (Fig. 4.11C. and 
D). Somewhat paradoxically, tryptophan supplementation contiguously in the presence 
of IFN-γ and/or 1-MT resulted in infectious yields equivalent to those detected for the 
control cultures. However, unlike the observation for the human isolates, the continuous 
culture in the presence of additional tryptophan did not result in enhanced (i.e. above 
normal medium) production of progeny for the animal isolates. 
 
 
Figure 4.11 Concurrent IDO1 inhibition and IFN-γ treatment completely prevented the loss of 
production of infectious progeny for the human strains and only partially prevented the IFN-γ 
induced loss of infectious progeny for the animal strains.  
The cultures were concurrently treated with 0.1 or 1 U ml-1 IFN-γ and/or 0.8 mM 1-MT as indicated on 
the figure with media and reagents replacement every 24 h. The infectious yield at 72 h PI is shown on 
each of the graphs. Legend is included to the right of the figure that indicates each culture condition (# 
indicates completely lethal). Data are mean ± SEM with n = 20. ***p < 0.001, Student’s two tailed t test. 
Significant differences were detected for all four strains when 0.1 U ml-1 IFN-γ was compared to 0.1 U 
ml-1 IFN-γ with 1-MT and when 1 U ml-1 IFN-γ was compared to 1 U ml-1 IFN-γ with 1-MT), (A) The 
infectious yield of AR39 at 72 h PI under each of the growth conditions is indicated in the figure, (B) The 
infectious yield of AO3 at 72 h PI under each growth, (C) The infectious yield of LPCoLN at 72 h PI 
under each growth, (D) The infectious yield of B21 at 72 h PI under each growth. 
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4.5.9 Investigation of potential IFN-γ or IDO1 downstream tryptophan acquisition 
mechanisms which may differentiate the human and animal C. pneumoniae 
isolates. 
The observation that IDO1 inhibition during IFN-γ tryptophan depletion of the host 
cells can completely overcome the IFN-γ effect for the human strains, but not for the 
animal strains, even though supplementation of tryptophan could rescue the cultures, 
implies that there is a tryptophan-dependent effect. These findings, combined with the 
reduced susceptibility to tryptophan depletion for the animal strains, may indicate that 
the animal isolates have alternative means to overcome IFN-γ tryptophan limitation. 
Whilst there is no evidence of tryptophan biosynthesis capability in the LPCoLN or B21 
genomes (or indeed any C. pneumoniae genome), we decided to rule out that products 
downstream of IDO are not the means by which the animal strains have reduced 
susceptibility to IFN-γ, possibly by anabolism of downstream metabolites in the 
kynurenine pathway. As shown in Fig. 4.12, IFN-γ treatment resulted in the expected 
reduced infectious yield, with higher IFU observed when IFN-γ and 1-MT were both 
present in the cultures, and the IFU was completely restored to control levels by 
contiguous culture with IFN-γ, 1-MT, and exogenous tryptophan. Addition of 
downstream metabolites of tryptophan from IDO, including; L-kynurenine, 3-hydroxy-
DL-kynurenine, indole, anthranilic acid at 48 h PI (96 h after IFN-γ and 1-MT treatment 
commenced) did not rescue the production of infectious progeny of any isolate (Fig. 
4.12.). We observed a comparable lack of rescue capability when we conducted a 
similar experiment to the tryptophan rescue experiment using kynurenine metabolites. 
Specifically, at 48 h PI we removed IFN-γ and added the kynurenine pathway 
metabolites, instead of tryptophan, in an attempt to rescue the production of infectious 
progeny. We did not observe any rescue above the control IFN-γ only treatment 
condition (Fig. 4.13). Thus, the differences between the human and animal strains do 
not relate to an unexpected ability to biosynthesise tryptophan or another role relating to 
the metabolites produced by the kynurenine pathway. 
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Figure 4.12  Downstream metabolites of IDO were not able to rescue the growth of IFN-γ and 1-MT 
cultures of all of the C. pneumoniae isolates.  
The figures shows the  infectious yield of cultures from a ‘rescue experiment’, where IFN-γ and L- 1MT 
treated cultures were supplemented with IDO metabolites (L-kynurenine, 3-hydroxy-DL-kynurenine, 
indole, 5-Bromo-N-(carboxymethyl) anthranilic acid, indicated in the key to the right) at 48 h PI and 
viability was measured at 96 h PI. Legend included to the right of the figure indicates the conditions for 
the experiment and # indicates lethality or no detectable inclusion forming units. Data are mean ± SEM 
with n = 20. ***p < 0.001, Student’s two tailed t test. Significant differences were observed for all four 
strains when 1 U ml-1 IFN-γ was compared to the 1 U ml-1 IFN-γ with 1-MT with L-trp rescue condition. 
(A) The infectious yield of AR39 at 96 h PI under each growth, (B) The infectious yield of AO3 at 96 h 
PI under each growth condition, (C) The infectious yield of LPCoLN at 96 h PI under each growth 
condition, (D) The infectious yield of B21 at 96 h PI under each growth condition. 
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Figure 4.13 Downstream metabolites of IDO1 are not advantageous to the C. pneumoniae isolates.  
The figures shows the  infectious yield of cultures from a ‘rescue experiment’, where IFN-γ treated 
cultures were supplemented with IDO metabolites (L-kynurenine, 3-hydroxy-DL-kynurenine, indole, 5-
Bromo-N-(carboxymethyl) anthranilic acid, indicated in the key to the right) at 48 h PI and viability was 
measured at 96 h PI. Legend included to the right of the figure indicates the conditions for the experiment 
and # indicates no detectable inclusion forming units. Data are mean ± SEM with n = 20. ***p < 0.001, 
Student’s two tailed t test. Significant differences were observed for all four strains when 1 U ml-1 IFN-γ 
was compared to the 1 U ml-1 IFN-γ with L-trp rescue condition. (A) The infectious yield of AR39 at 96 h 
PI under each growth, (B) The infectious yield of AO3 at 96 h PI under each growth condition, (C) The 
infectious yield of LPCoLN at 96 h PI under each growth condition, (D) The infectious yield of B21 at 96 
h PI under each growth condition. 
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4.5.10 Investigation of the potential C. pneumoniae mechanisms which could 
target the host trafficking pathways to exploit tryptophan pool 
 
Intracellular pathogens are known to manipulate host trafficking and biosynthetic 
pathways to acquire nutrients for its growth (Eisenreich et al., 2013). Therefore the 
ability of C. pneumoniae isolates to manipulate tryptophan from the host cell pool into 
chlamydial inclusions was tested. In order to investigate this alternative strategy, which 
could possibly explain the reduced susceptibility of animal C. pneumoniae, isolates to 
IFN-γ mediated tryptophan depletion; an analogue of L- tryptophan (5-flourotrytophan) 
was used. This analogue gets incorporated into cellular proteins in the place of 
tryptophan and results in the inhibition of host and the bacterial (tryptophan auxotroph) 
growth (Carlson et al., 2006; Wood et al., 2003). In this experiment, BEAS-2B cells 
were infected with human AR39 and animal LPCoLN isolates (MOI of 1) and were 
cultured in tryptophan depleted medium, which was supplemented with a range of 5-
fluorotryptohan (5 - 50 mg l-1) concentrations. As shown in Figure 4.14, the infectious 
yield of C. pneumoniae isolates were inhibited by the addition of increasing 
concentrations of 5-flourotrytophan. The human and animal C. pneumoniae isolates 
showed marginal differences between 5-fluorotryptohan sensitivity, with 10 mg l-1 5-
fluorotryptohan resulting in 0.5 log fewer IFU ml-1 and higher concentrations (20 - 50 
mg l-1) of 5-fluorotryptohan resulting in 1 log less IFU ml-1 compared to untreated 
controls (0 mg l-1 5F-Trp) of AR39 (Fig. 4.14 A). It was also observed that the higher 
concentration of 5-fluorotryptohan (20 - 50 mg l-1) was toxic to the host cells. 
Furthermore, the animal LPCoLN isolate showed relatively minor reductions in the 
infectious yield compared to the yield in the controls (1 and 2 log fewer IFU ml-1 with 
30 and 50 mg l-1 of 5-fluorotryptohan respectively) (Fig. 4.14 B). As compared to the 
controls (0 mg l-1 5F-Trp), no difference was observed in the animal C. pneumoniae 
isolate sensitivity to 5-fluorotryptohan, clearly stating the absence of any potential 
animal C. pneumoniae mechanisms which could target the host trafficking pathways to 
acquire tryptophan. 
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Figure 4.14 Growth of human and animal C. pneumoniae isolates in the presence of 5-
fluorotryptohan.  
BEAS2B cells were infected with C. pneumoniae AR39 and LPCoLN isolates (MOI 1) in tryptophan 
depleted medium and were supplemented with increasing concentrations (5-50 mg l-1) of 5-
fluorotryptohan. The infectious yield at 72 h PI is shown on each of the graphs. Legend is included to the 
right of the figure that indicates each culture condition. Data are mean ± SEM with n = 20. ***p < 0.001, 
Student’s two tailed t test. Statistics were conducted using Student’s two tailed t test (***p < 0.001) 
relative to the control (0 mg l-1 5F-Trp).  (A) The infectious yield of AR39 at 72 h PI under each of the 
growth conditions is indicated in the figure and (B) The infectious yield of LPCoLN at 72 h PI under each 
growth conditions is indicated in the figure. 
 
4.5.11 Tryptophan levels are reduced by addition of IFN-γ to the cultures for both   
animal and human C. pneumoniae strains 
Direct inhibition of IDO activity has been reported for certain bacteria capable of 
inducing direct or indirect production of nitric oxide (Hucke et al., 2004). Therefore, 
tryptophan catabolism, production of nitric oxide and the induction of iNOS was 
assessed in these cultures. The amount of free tryptophan was measured in culture 
supernatants (Ibana et al., 2011) and as shown in Table 4.4, the addition of IFN-γ to any 
culture conditions, including uninfected cells, resulted in significant reductions in 
tryptophan levels. For example, BEAS-2B has 95.88 µM (standard deviation (SD): ± 
13.77 µM) tryptophan under standard conditions, but this was reduced to 2.70 µM (SD: 
± 1.42 µM) in the presence of 1 U ml-1 IFN-γ (p<0.0001; Student’s t test). There were 
some differences between the tryptophan levels for each isolate under the standard 
culture conditions, but these are more likely associated with the slightly different 
growth phases of each organism and relative abundance of progeny, rather than a direct 
indication of tryptophan usage. In addition, free intracellular amino acid concentrations 
of asparatic acid, glucose, aspargine, serine, glutamine, glycine, threonine, arginine, 
alanine, valine and isoleucine were also determined in culture supernatants (Table 4.5). 
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Next, to assess the production of nitric oxide, the levels of nitrite in the culture 
supernatants were measured by the standard Greiss reagent assay. Nitrite levels were 
measured in C. pneumoniae (Human AR39 or animal LPCoLN isolates) infected 
BEAS-2B cells at 48 h PI under conditions stated in Table 4.6. C. pneumoniae infected 
BEAS-2B cells did not to produce nitric oxide in cultures (Table 4.6). The nitrite 
concentrations in infected culture supernatants under all treatment conditions, including 
the positive controls, were below the standard detection limit (2.5 µM) of the assay. 
Finally, with the exception of positive control (RAW cells stimulated with IFN-γ and 
LPS), western blot analysis also demonstrated the absence of iNOS induction in all the 
C. pneumoniae infected culture conditions (Fig. 4.15). 
 
Table 4.4 Metabolomics measurement of L-tryptophan at 72 h PI 
                                      No IFN-γ                 1 U ml-1 IFN-γ 
BEAS-2B     95.88 ± 13.77            2.70 ± 1.41*** 
Human AR39            73.58 ± 6.16              4.27 ± 2.34*** 
Human AO3           141.67 ± 8.79           2.11 ± 1.79*** 
Koala LPCoLN      102.21 ± 4.19           1.62 ± 1.41*** 
Bandicoot B21         58.17 ± 3.66               1.87 ± 1.63*** 
Data shown are mean ± SD (n = 3) µM L-tryptophan *** p< 0.0001 compared to the control culture (no treatment). 
Statistical analyses were performed using Student’s two tailed t test. 
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Table 4.5 Metabolomics measurement of amino acids at 72 h PI 
 BEAS-2B Human AR39 Human AO3 Koala LPCoLN Bandicoot B21 
 No IFN-γ 1 U ml-1 IFN-γ No IFN-γ 1 U ml-1 IFN-γ No IFN-γ 1 U ml-1 IFN-γ No IFN-γ 1 U ml-1 IFN-γ No IFN-γ 1 U ml-1 IFN-γ 
Asparatic Acid 1953 ± 227.8 1683 ± 121.8 1823 ±  71.95 2011 ±  36.15 2052 ± 112.5 2009 ±  153.9 1942 ± 78.02 2310 ± 70.99 1792 ± 73.74 2163 ± 2073 
Glucose 6771 ± 787.8 5399 ±  392.1 5959 ± 232.7 6265 ± 131.6 5499 ±  291.0 5920 ±  453.4 6156 ± 248.2 7341 ± 190.4 6472 ± 258.6 6497 ±  69.34 
Aspargine 3056 ± 359.0 2861 ± 205.5 2621 ± 84.18 3425 ±  74.55 3157 ± 165.0 3471 ±  252.1 2691 ±  114.9 3907 ±  121.2 2492 ± 101.5 3758 ± 46.76 
Serine 166.9 ± 19.08 1614 ± 111.9 160.4 ± 4.57 1667 ± 36.55 447.7 ± 21.86 2352 ± 182.60 201.1 ±  8.82 1910 ±  8.82 128.1 ±  6.22 2549 ±  27.77 
Glutamine 3549 ± 5572 7500 ±  4772 3894 ± 5136 3465 ± 4903 4811 ±  4692 6620 ± 2701 2151 ± 3478 1960 ± 2360 5778 ± 4720 5193 ±  4303 
Glycine 2276 ±  268.5 3081 ±  809.3 2634 ± 1471 1842 ± 1915 3292 ± 173.2 3205 ±  343.9 971.8 ±  343.9 3500 ± 1598 2028±  895.1 2860 ±  1414 
Threonine 913 ±  123.3 1840 ± 7717.7 1294 ±  717.0 935.4 ±  968.7 1309 ±  69.93 1964 ± 163.7 66.7 ± 577.4 1723 ± 752.2 1023 ± 554.8 1431 ± 695.0 
Arginine 1063 ± 1094 9285 ± 2071 7796 ±  4074 3478 ±  3568 10666 ± 514.0 9979 ± 709.50 5404 ±  5002 8558 ± 4512 9245 ± 565.1 9400 ±  1572 
Alanine 6183 ± 724.9 3697 ±  1206 5242 ±  500.7 3012 ±  2900 6397 ± 337.3 5120 ± 432 1663 ± 2878 4839 ± 734.4 4218 ± 1405 4344 ± 1787 
Valine 509 ± 61.26 1871 ± 1204 992.4 ± 682.5 783.7 ± 920.30 1051 ± 55.28 1634 ± 115.20 568.9 ± 506.1 1473 ± 824.50 727.2 ± 719 1161 ± 765.50 
Isoleucine 1537 ± 181.40 2204 ± 160.2 1502 ± 58.46 2598 ± 46.80 2047 ± 100.8 2006 ± 150.90 1753 ± 75.84 2663 ± 81.06 1119 ± 44.42 2147 ± 24.39 
Data shown are mean ± SD (n=3) 
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Table 4.6 Nitrite concentrations of C. pneumoniae infected BEAS-2B cells 
Treatments Human AR39 (µM) Animal LPCoLN (µM) 
Infection only -0.91 ± 1.18 -0.19 ± 0.20 
IFN-γ only 0.87 ±0.07 1.87 ± 0.11 
1-MT only 0.53 ± 0.05 2.26 ± 0.50 
L-Trp only 1.05 ± 0.62 1.84 ± 0.08 
L-Arg only 1.52 ± 0.02 1.70 ± 0.28 
L-Trp + 1-MT 0.96 ± 0.60 1.99 ± 0.57 
IFN-γ + 1-MT 0.82 ± 0.46 2.32 ± 0.44 
IFN-γ + 1-MT + L-Trp 1.56 ± 0.74 2.11 ± 0.46 
IFN-γ + L-Arg 3.25 ± 2.31 2.08 ± 0.32 
IFN-γ + L- Arg + L-Trp 1.36 ± 0.30 1.23 ± 0.38 
IFN-γ + L- Arg + L-Trp + 1-MT 1.33 ± 1.07 0.03 ± 1.24 
IFN-γ + LPS (positive control) -0.72 ± 0.46 -1.07 ± 0.36 
Nitrite concentrations were determined in culture supernatants at 48 h PI. Data are presented as µM nitrite and 
represent the mean ± SD of 2 independent experiments. 
 
 
 
Figure 4.15 Absence of iNOS induction in C. pneumoniae infected BEAS-2B cells.  
Western blot analysis of iNOS expression in BEAS-2B cells infected with human AR39 and animal 
LPCoLN isolates were performed at 48 h PI. β-actin was used as a loading control. Lanes 1-13 represents 
: Infection only, IFN-γ only, 1-MT only,  L-Trp only,  L-Arg only,  L-Trp + 1-MT, IFN-γ + 1-MT,  IFN-γ 
+ 1-MT + L-Trp , IFN-γ + L-Arg , IFN-γ + L- Arg + L-Trp , IFN-γ + L-Arg + L-Trp + 1-MT, IFN-γ + 
LPS and  positive control (RAW cells + IFN-γ + LPS). 
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4.5.12 C. pneumoniae strains are sensitive to murine IFN-γ when cultured in 
mouse cells 
 Mouse IFN-γ in mouse cell lines does not induce IDO but instead induces GTPases that 
act as a different mechanism of defence against intracellular pathogens, such as 
Chlamydia (Nelson et al., 2007). Therefore, we decided to investigate if the animal C. 
pneumoniae strains are sensitive under these conditions. The mouse cell line McCoy B, 
a mouse fibroblast model commonly used in chlamydial studies was used for these 
experiments. The human strains showed a significantly reduced ability to grow in the 
mouse cells, even in the absence of IFN-γ treatment. The strains were infected at a MOI 
of 0.1 in the same cell numbers as used for BEAS-2b cells, yet far fewer infectious 
progeny were produced by the human strains (Fig. 4.16A. and B.). The addition of 
mouse IFN-γ at either 25 or 50 U ml-1 resulted in substantially less (~3 log) infectious 
yield for both human isolates, AR39 and AO3, at 48 h PI compared to the controls (Fig. 
4.16A. and B.). The animal strains showed a similar production of infectious progeny 
from growth in McCoy B cells as that observed from BEAS-2B cells. Treatment of the 
McCoy B cells with either 25 U ml-1 or 50 U ml-1 of mouse IFN-γ resulted in 1.5 or 2.5 
log less infectious yield compared to that observed in the controls for both C. 
pneumoniae LPCoLN and B21. We conducted a tryptophan rescue experiment on these 
cultures where the IFN-γ treatment was removed at 48 h PI and exogenous tryptophan 
(200 µg ml-1) added to ‘rescue’ the cultures. The cultures were continued for a further 
48 h (96 h PI) and the infectious yield was determined. The human strains showed even 
greater reductions in infectious yield at 96 h PI in the presence of IFN-γ which was not 
restored at all by the addition of tryptophan. The animal strains showed a lower drop in 
infectious yield compared to the yield in the controls (3 and 4 log less for LPCoLN and 
B21 respectively) when cultured in McCoy cells treated with mouse 50 U IFN-γ at 96 h 
PI and the addition of tryptophan did not restore the growth  (Fig. 4.17C. and D.). 
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Figure 4.16 All of the C. pneumoniae strains are susceptible to mouse IFN-γ when cultured in mouse 
McCoy B cells. 
 The graphs show the infectious yield ml-1 at 48 h PI when cultures were grown in the presence of either 
25 U or 50 U IFN-γ at an MOI of 0.1. The legend is included to the right of the figure that indicates the 
conditions for each experiment. Data are mean ± SEM with n = 20. ***p < 0.001, Student’s two tailed t 
test. Significant differences were identified for all four strains when the control (No IFN-γ) was compared 
to 25 U ml-1 IFN-γ and 50 U ml-1 IFN-γ. (A) The infectious yield (IFU ml-1) of C. pneumoniae human 
strain AR39 from cultures harvested at 48 h PI. (B) The infectious yield (IFU ml-1) of C. pneumoniae 
human strain AO3 from cultures harvested at 48 PI. (C) The infectious yield (IFU ml-1) of C. pneumoniae 
animal strain LPCoLN from cultures harvested at 48 h PI. (D) The infectious yield (IFU ml-1) of C. 
pneumoniae animal strain B21 from cultures harvested at 48 h PI. 
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Figure 4.17 Tryptophan rescue does not restore the IFN-γ inhibition of production of infectious 
progeny for any of the C. pneumoniae strains cultured in mouse cells.  
The graphs show the yield of inclusion forming units ml-1 at 96 h PI when cultures were grown in the 
presence of either 25 U ml-1 or 50 U ml-1 IFN-γ at an MOI of 0.1, were either cultured under these 
conditions until 96 h PI, or were ‘rescued’ at 48 h PI by removal of the IFN-γ and replacement with L-
tryptophan supplemented media. The key to the right of the figure indicates the conditions for each 
experiment and # represents lethality or no detectable inclusion forming units. Data are mean ± SEM (n = 
20), p > 0.05; *p< 0.05; Student’s two tailed t test identified significant differences for all strains when 25 
U ml-1 IFN-γ was compared to 25 U ml-1 IFN-γ with L-trp  Rescue or when 50 IFN-γ was compared to 50 
U ml-1 IFN-γ with tryptophan rescue.(A) The infectious yield (IFU ml-1) of C. pneumoniae human strain 
AR39 from cultures harvested at 96 h PI. (B) The infectious yield (IFU ml-1) of C. pneumoniae human 
strain AO3 from cultures harvested at 96 h PI. (C) The infectious yield (IFU ml-1) of C. pneumoniae 
animal strain LPCoLN from cultures harvested at 96 h PI. (D) The infectious yield (IFU ml-1) of C. 
pneumoniae animal strain B 21 from cultures harvested at 96 h PI. 
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4.6 DISCUSSION 
It is quite remarkable that a major determinant of tissue tropism and a major defence 
mechanism of IFN-γ attack against chlamydiae appear to be almost exclusively via 
tryptophan depletion (Morrison, 2000; Nelson et al., 2005). This defence mechanism 
appears to have selected for chlamydial host specific adaptations such as C. muridarum 
cytotoxin production (Nelson et al., 2007) and C. caviae’s ability to biosynthesise this 
essential amino acid (Wood et al., 2004a). However, C. pneumoniae, the species which 
has the most broad host range of all Chlamydia described to date, has the most limited 
collection of tryptophan related apparatus within their genomes, with no evidence of 
biosynthesis or regulation (i.e. no trpR) of tryptophan. 
A model whereby transcription attenuation mediated by tryptophan content of 
chlamydial proteins, and the specific proteins in which the tryptophan content is altered 
leads to transcription attenuation, has been proposed to explain altered sensitivity to 
tryptophan depletion (Lo et al., 2012). One protein which features heavily in this model 
is the tryptophan transporter TyrP, which does have a higher tryptophan content in 
Chlamydia than homologs in other bacterial genera (Lo et al., 2012), and it is proposed 
that the increased tryptophan burden of this (and other) proteins during tryptophan 
limitation, increases the likely downstream signalling to tryptophan mediated 
transcription attenuation. However, there is no difference in the tryptophan content of 
the TyrP protein sequence between C. pneumoniae AR39 and LPCoLN (Mitchell et al., 
2010a). Secondly, the overall tryptophan usage in the genome of LPCoLN is 1.6% (less 
susceptible to tryptophan levels), whereas the % of tryptophan in the AR39 genome is 
1.0% (Mitchell et al., 2010a). Therefore, whilst it is an appealing explanation, this 
model is not supported by the observations we present here with C. pneumoniae animal 
and human strains. 
There have also been some observations in relation to differences in tyrP copy numbers 
and coding sequence between C. pneumoniae strains, and speculation that this may 
mediate tissue trophism (Gieffers et al., 2003a), however, this was based on a limited 
number of genomes of only human isolates. Additionally, the biochemical activity of 
the chlamydial tyrP protein has not been established, so this proposal remains quite 
speculative. However, we note that the isolates in this study all have one copy number 
except AR39, which has two copies, and there are a few SNPs between the animal (B21 
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and LPCoLN) and human sequences (Gieffers et al., 2003a; Myers et al., 2009; Roulis 
et al., 2014), but not in areas with predicted functional significance. 
Consistent with these genome annotations, C. pneumoniae TW183 (a respiratory 
isolate) (Byrne et al., 2001), AO3 (a heart aorta isolate) (Pantoja et al., 2001), CV-6 
(cardiovascular isolate) (Bellmann-Weiler et al., 2010), BAL-37 and BAL-36 
(broncheolar lavage isolates) (Mehta et al., 1998; Pantoja et al., 2000b) have all been 
demonstrated to be sensitive to IFN-γ treatment during culture in epithelial or 
endothelial cells, and were able to be rescued or restored by tryptophan addition or by 
the inhibition of IDO. There appears to be IFN-γ dose-dependent differences between 
the sensitivity of the C. pneumoniae strains, with some requiring quite high doses before 
sensitivity was observed (up to 400 U ml-1), and indeed AO3 and BAL-16 direct 
comparisons indicate some differences in sensitivity (Mehta et al., 1998). However, we 
suspect that there are two major factors which mean that it is not possible to directly 
compare these findings. Firstly, anecdotal reports of batch-dependent variation in 
activity (even though suppliers report units of activity) for IFN-γ activity from many 
laboratories, as well as our own direct observations. Secondly, the time of IFN-γ 
addition to the cultures is quite critical for the degree of impact on chlamydial viability 
and their ability to infect, and this varies considerably between these studies (i.e. 24 h 
prior to infection, or at the commencement of infection, or during infection have all 
been reported in these previous studies). Hence, it is likely but not conclusive, that there 
are differential sensitivities to IFN-γ between C. pneumoniae strains. Our previous work 
has shown that the koala isolate LPCoLN is likely to be an ancestor to some human C. 
pneumoniae, which leads us to speculate that perhaps C. pneumoniae from animal hosts 
that show more acute and aggressive disease symptoms, may have distinct sensitivities 
to tryptophan depletion when compared to the more recently evolved human adapted 
isolates. In order to test this hypothesis, we used two human isolates and two animal 
isolates and investigated their susceptibility to human and animal IFN-γ treatment 
conditions. The human isolates come from chronic respiratory (AR39) and coronary 
(AO3) cases whereas the animal C. pneumoniae included the koala (LPCoLN) and 
bandicoot (B21). 
Here we report that human C. pneumoniae isolates are more sensitive to tryptophan 
availability than the animal isolates (in both a relevant respiratory cell line, and also in a 
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commonly used cell line, Hep-2). The human AR39 and AO3 isolates both showed 
complete loss of viability at low doses of IFN-γ and this corresponded to the 
observation of persistence type morphologies, with smaller inclusions sizes, and fewer 
larger cell structures, in these cultures during IFN-γ conditions. We confirmed that IDO 
was being expressed under these conditions and using a metabolomics approach showed 
that tryptophan was indeed depleted. Therefore, in spite of the greater than 1000 genes 
known to be induced under these conditions (Pawliczak et al., 2005), the IFN-γ activity 
against human C. pneumoniae strains in human lung cells appears to be acting solely via 
tryptophan depletion. Interestingly, when we provided the human strains with still 
higher levels of tryptophan, by culturing them with concurrent IFN-γ treatment and/or 
L- 1MT with tryptophan supplementation (200 µg ml-1), we observed infectious yields 
that were even greater than the controls. We know from the metabolomics data that in 
the media ~10 µg ml-1 of tryptophan was still present even after 72 hours of culture. 
This growth enhancement by tryptophan supplementation suggests that either; 1. there 
were low levels of IDO activity even in the absence of IFN-γ (not detectable by the 
western blot in Fig. 4.7) or, 2. that these human strains are more responsive to 
tryptophan, both at high and low levels, and can adapt to both down-regulate their 
growth via entering persistence or increase production of infectious progeny under 
favourable conditions. The AO3 cardiovascular isolate did show a greater sensitivity to 
tryptophan depletion; it also showed highly efficient recovery when exogenous 
tryptophan was added to the cultures, suggesting that perhaps this strain is highly 
adapted to entry and recovery from persistence in response to tryptophan bioavailability. 
The data presented here indicate three major distinctions for the animal isolates 
compared to the human isolates. Firstly, the animal isolates showed comparatively little 
sensitivity to IFN-γ-driven tryptophan depletion compared to the sensitivity observed 
for the human isolates. Secondly, there was little evidence of persistence with the 
animal isolates but much more evidence with the human isolates. Thirdly, these minor 
reductions with the animal strains in comparison especially to the AO3 human strain, 
showed comparably less restoration of infectious progeny or rescue by inhibition of 
IDO activity, or tryptophan rescue experiments at 48 h PI. Specifically, the IFN-γ 
reductions in infectious yield were only partially restored by IDO inhibition, unless this 
inhibition was conducted with concurrent tryptophan treatment. In addition, the 
infectious yield reductions were not as well recovered by the removal of IFN-γ and 
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‘rescue’ by culture in the presence of tryptophan. Our data has also demonstrated that 
there appears to be no role for the downstream metabolites of the kynurenine pathway. 
Even though the genome does not suggest any additional biochemical pathways that 
might enable synthesis of tryptophan, our biological data also supports a lack of such 
rescue with C. pneumoniae. These data combined, suggest that the animal isolates are 
not able to readily adapt to tryptophan limitation by the induction of a persistence mode 
of growth that can be subsequently rescued. This is particularly the case when compared 
to the human AO3 isolate, which showed sensitivity at comparatively lower IFN-γ doses 
that were able to be considerably recovered or restored levels by either tryptophan 
rescue experiments or concurrent treatment with IFN-γ and IDO inhibition. 
Both the animal and human isolates were sensitive to mouse IFN-γ treatment of McCoy 
cells and this sensitivity was not rescued at all by the addition of exogenous tryptophan. 
This observation fits with previous findings that in some murine cells such as the 
McCoy B cells used here, IFN-γ does not induce IDO, but instead induces GTPases (de 
la Maza et al., 1985; Nelson et al., 2005; Roshick et al., 2006). The C. muridarum 
genome has a cytotoxin that has been proposed to cleave and inactivate these GTPases 
(Nelson et al., 2005). The C. pneumoniae genome does not contain any similar toxin, 
supporting the fact that it does not possess a similar mechanism to the mouse strain of 
Chlamydia. This cytotoxin, or at least the comparative resistance to IFN-γ, is likely a 
rodent-specific adaption for this Chlamydia because rodents (unlike many other 
animals) do not induce the IDO1-kynurenine pathway to the same level or in as many 
tissue locations as the immune activation of IDO1 that has been reported in non-human 
primates, gerbils, and guinea pigs (reviewed by (Murakami and Saito, 2013b)). In 
addition to this, there is evidence that the IFN-γ activates IDO1 tryptophan depletion in 
sheep cells (Brown et al., 2001). We have recently identified that IFN-γ gene is present 
in the koala transcriptome and that the IFN-γ gene expression was induced when koala 
peripheral blood mononuclear cells were incubated with Chlamydia pecorum (Mathew 
et al., 2013a). IDO1 and IDO2 are also present in the koala transcriptome (Unpublished 
communication, Timms). Thus, tryptophan depletion in response to immune activation 
is likely a common host defence mechanism, and yet in spite of this likely conservation, 
we have clearly identified human and animal strain differences in susceptibility to this 
mechanism. 
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Therefore, we propose that the human isolates are exquisitely and positively sensitive to 
tryptophan availability and are able to sense decreasing levels of tryptophan in the face 
of host cell IFN-γ attack. This is a host-specific adaptation that allows them to more 
readily enter into persistence and hence chronic growth under conditions that are 
tryptophan limited.  Perhaps not surprisingly, we also see differences in this “strategy” 
between human isolates, with the heart strain AO3 showing the most rapid response to 
enter persistence but also having the highest level of recoverable infectious yield when 
adequate tryptophan levels return. Combined these data demonstrate that C. pneumoniae 
strains that have adapted to the human host have exquisite tryptophan sensitivity and 
have adaptability that may reflect the chronic nature of the infections in humans. 
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5.2 ABSTRACT 
 
Chlamydia pneumoniae strains have recently been demonstrated to have substantially 
different capacities to enter and recover from IFN-γ induced persistence, depending 
on whether they are from human or animal host sources. Here we examined the 
ability of two human and two animal strains to enter and be rescued from penicillin 
induced persistence. The ability to form inclusions after the addition of penicillin was 
much reduced in the two animal isolates (koala LPCoLN, bandicoot B21) compared 
to the two human isolates (respiratory AR39, heart A03). The penicillin treatment 
resulted in a dose dependent loss of infectious progeny for all isolates, with the 
human strains failing to produce infectious progeny at lower doses of penicillin than 
the animal strains. The most remarkable finding however was the contrasting ability 
of the isolates to recover infectious progeny production after rescue by removal of 
the penicillin (at 72 h) and continued culture. The animal isolates both showed 
virtually no recovery from the penicillin treatment conditions. In contrast, the human 
isolates showed a significant ability to recovery infectivity, with the heart isolate 
(A03) showing the most marked recovery. Combined, these data further support the 
hypothesis that the ability to establish and recover from persistence appears to be 
enhanced in human Chlamydia pneumoniae strains compared to animal strains. 
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5.3 INTRODUCTION 
 
Chronic chlamydial infections have been linked to ocular, urogenital and respiratory 
infections in humans (reviewed in Zhong, 2009). Several studies argue that 
Chlamydia associated chronic infections are caused by persistent forms of the 
bacteria (Hogan et al., 2004b; Schoborg, 2011). The persistence phase is thought to 
enable Chlamydia to avoid host immune responses and help maintain long-term 
infection within the host (reviewed in Wyrick, 2010a). Chlamydial persistence can be 
induced by several stimuli, including the presence of other intracellular pathogens, 
IFN-γ addition, and nutrient depletion such as amino acid withdrawal and iron 
limitation and as used in this study, antibiotic (penicillin G) exposure (reviewed in 
Hogan et al., 2004b). Early clinical observations reported the isolation of C. 
trachomatis in urethritis and cervicitis patients several months following penicillin 
treatment (Holmes et al., 1967; Richmond et al., 1972). As a result of these clinical 
observations, penicillins are no longer considered for anti-chlamydial therapy. It is 
also important to recognize that penicillins are routinely used to treat other bacterial 
infections (Bartholow, 2011; CDC, 2010) and hence individuals who are treated for 
their main infection but are also asymptomatically infected with Chlamydia, might 
still come in contact with these β-lactams and cause chronic infections in the host. 
There is an abundance of evidence supporting the notion  that Chlamydia can enter a 
persistent state in vitro, with studies using various cell lines and different strains of 
Chlamydia (reviewed in Hogan et al., 2004b; Schoborg, 2011). In the early 1970s, 
Galasso and Manire demonstrated that C. psittaci MN/Cal-10 cultured in the 
presence of penicillin G and antiserum, was maintained in cultures for up to 9 
months in a viable, non-infectious state and that upon the removal of the stressor the 
productive developmental cycle was resumed (Galasso and Manire, 1961; 
Matsumoto and Manire, 1970). Ultrastructural analysis of penicillin G exposed C. 
psittaci MN/Cal-10 revealed the presence of aberrant enlarged irregular RB forms 
and shows the inhibition of RB to EB differentiation in these cultures (Matsumoto 
and Manire, 1970). Similar observations were also reported with C. trachomatis 
serovars E and L2, where penicillin exposed cultures showed the presence of 
abnormal aberrant RBs (Skilton et al., 2009; Wyrick and Knight, 2004). These 
aberrant RB forms were also identified in vivo in penicillin G exposed C. 
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trachomatis infected mouse oviducts (Phillips et al., 1984). Additionally, penicillin 
G has been suggested to target only the RB stage of C. trachomatis serovar L2 
between 12 - 24 hours post infection and is shown to be ineffective when added at 
the later EB stage (24 hours post infection) (Dumoux et al., 2013). In C. trachomatis 
LGV infected cultures, penicillin treatment had no effect on the synthesis of the 
major outer membrane protein (MOMP), however the synthesis of 60 kilodalton 
cysteine-rich outer membrane protein of RBs was completely inhibited (Cevenini et 
al., 1988). This may explain the inhibition of RB division resulting in large aberrant 
persistent forms during penicillin treatment. Also, C. trachomatis serovars E and L2 
have been shown to remain viable and with unaffected chromosomal and plasmid 
replication during penicillin G exposure (Kintner et al., 2014; Lambden et al., 2006). 
Several studies have also examined the effects of penicillin exposure on C. 
pneumoniae. Human C. pneumoniae respiratory isolates (TW183, CWL-029, MUL-
1, Kajaani 7, and AR39) and the cardiovascular isolates (CV-1, and CV-3 to CV-6) 
have been reported to be susceptible to penicillin G exposure in epithelial cells 
(Gieffers et al., 1998; Wolf et al., 2000b).  
Our previous work (chapter 4) identified that the human isolates (AR39 and A03) 
were more sensitive to IFN-γ mediated tryptophan depletion than the animal isolates 
(LPCoLN and B21). As a result of tryptophan depletion, only the human isolates 
were able to divert their infectious cycle to a non-infectious, viable persisting phase 
and subsequently be able to reactivate their developmental cycle when adequate 
levels of available tryptophan were restored. Given these striking observations 
around the human adapted C. pneumoniae isolates, this suggested to us that perhaps 
there exists a lower threshold both to enter persistence, as well as to recover from 
persistence in the IFN-γ model. We therefore, examined whether this reflects a 
human C. pneumoniae specific IFN-γ mediated adaptation or implies a more 
generalized adaptation towards a preference for chronic growth by using penicillin G 
stressor. 
5.4 MATERIALS AND METHODS  
5.4.1 C. pneumoniae isolates and culture conditions 
The human C. pneumoniae pharyngeal isolate AR39 (ATCC 53592), A03 a human 
aortic isolate (Ramirez, 1996b), LPCoLN  a koala respiratory isolate (Wardrop et al., 
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1999) and B21 a bandicoot ocular isolate (Kumar et al., 2007b) was used in this 
study. BEAS-2B cells (sourced from the ATCC)  were routinely  used for the in vitro 
culturing of the isolates at a multiplicity of infection (MOI) of 0.1 in RPMI 1640 
culture medium (Invitrogen) supplemented with 10% heat inactivated fetal calf 
serum (Invitrogen, Australia) at 37˚ C in 5% CO2. C. pneumoniae isolates were 
treated with 50 to 500 U ml-1 of penicillin G (CSL Limited, Australia) at 4 h PI and 
the viable infectious yield, inclusion morphology, % of infectivity were measured at 
72 h PI (Fig 5.1). For reversion experiments, penicillin was removed by three media 
washes and the cultures were replaced with fresh media at 72 h PI. Eventually, these 
cultures were harvested at 144 h PI for the measurement of chlamydial viability (Fig 
5.1). Control culture conditions (without penicillin G treatments) for all the four 
isolates at 72 and 144 h PI were included in the experiments.  
 
 
 
 
 
 
 
 
Figure 5.1 Experimental layout of culture conditions used in this chapter. 
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5.5 RESULTS 
5.5.1 Penicillin G treatment reduces the infectious progeny production in both 
human and animal C. pneumoniae isolates 
To investigate the impact of penicillin G, on the ability of both human and animal C. 
pneumoniae isolates to produce infectious EBs, BEAS-2B cells were infected at an 
MOI of 0.1 with human or animal C. pneumoniae isolates. At 4 h PI, penicillin G 
was added in a range of concentrations (50 to 500 U ml-1) and was maintained in the 
culture until 72 h PI. These cultures were harvested in SPG and the cell lysates were 
sub-passaged to measure the production of infectious EBs. It was observed that both 
the human C. pneumoniae isolates were susceptible to penicillin G treatments. The 
human isolates both showed reduced ability to generate infectious EBs, with 50 U 
ml-1 penicillin G resulting in 1 log fewer IFU ml-1 compared to untreated controls for 
strain AR39 (Fig.5.2 A) and 2.5 log less IFU ml-1 for strain AO3 compared to the 
control conditions (Fig.5.2 B). Both the human isolates also showed a 2.5 log drop at 
100 U ml-1 penicillin G and complete loss of infectious EBs at 200 and 500 U ml-1 of 
penicillin G, as compared to the untreated controls at 72 h PI (Fig.5.2 A and 5.2 B). 
The two human isolates showed differences in sensitivity to penicillin treatment, 
with A03 more sensitive with a ~2 log loss of infectious progeny after 50 U ml-1 
(1139 IFU ml-1 at 50 U compared to 361265 IFU ml-1 in the control) penicillin and 
AR39 showing ~1 log less infectious units at the same dose (22073 IFU ml-1 at 50 U 
compared to 325672 IFU ml-1 in the control) (average titers are indicated when 
numbers provided). The fold change (FC) data (Table 5.1) support the increased 
sensitivity of A03 to penicillin treatment with 50 U ml-1 penicillin causing a 0.03 FC 
in yield compared to the untreated control, while AR39 FC of yield relative to the 
control was 0.06 at this penicillin dose (Fig.5.2.(A, B)).  
The animal isolates also showed a similar loss of infectious progeny after penicillin 
treatment (Fig.5.2.(C, D)). Even though these strains produce much higher infectious 
progeny compared to the human strains, treatment with 50 U ml-1 of penicillin 
resulted in 0.04 FC for LPCoLN (2065000 IFU ml-1 from 50 U ml-1 compared to 
48580000 IFU ml-1untreated control), and 0.004 FC for B21 (227852 IFU ml-1with 
50 U ml-1 treatment compared to 47870000 IFU ml-1 in the control) at 72 h PI 
(Fig.5.2.(C,D)). The B21 isolate was more sensitive to penicillin than LPCoLN. All 
of the strains had no infectious inclusion forming units at 500 U ml-1 of penicillin at 
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72 h PI and both of the human strains also did not have detectable inclusion forming 
units at 200 U ml-1 of penicillin. 
 
 
 
 
 
Figure 5.2 Penicillin exposure reduces the infectious progeny production in both human and 
animal C. pneumoniae isolates 
The figure shows the infectious progeny of C. pneumoniae isolates following penicillin G exposure. 
BEAS-2B cells were infected at an MOI of 0.1 and penicillin G treatments were added at 4 h PI and 
continued until 72 h PI. The inclusion forming units ml-1 (IFU ml-1) are indicated on the Y-axis and 
different penicillin G treatments are indicated by grey scale shading (legend indicated at the right of 
the figure). # indicates that no infectious progeny was detected. Statistics were conducted using 
Students’s two- tailed t –test relative to the untreated controls (Data are mean ± SEM with n = 20; ***P 
< 0.001) (A)The infectious yield (IFU ml-1) of human AR39 C. pneumoniae isolate from cultures 
harvested at 72 h PI. (B)The infectious yield (IFU ml-1) of human AO3 C. pneumoniae isolate from 
cultures harvested at 72 h PI. (C)The infectious yield (IFU ml-1) of animal LPCoLN C. pneumoniae 
isolate from cultures harvested at 72 h PI. (D) The infectious yield (IFU ml-1) of animal B21 C. 
pneumoniae isolate from cultures harvested at 72 h PI. 
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             Table 5.1 Fold change data of inclusion forming units compared to the controls for each isolate during penicillin G treatment at 72 h PI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                # 0 indicates no fold change was analysed due the absence of infectious progeny in these cultures. Data are mean ± SEM.
      50 PEN           100 PEN 200 PEN 500 PEN 
Human AR39 0.0677 ± 0.0059       0.0037 ± 0.0005           # 0        # 0 
Human AO3 0.0031 ± 0.0005       0.0031 ± 0.0005           # 0         # 0 
Koala LPCoLN 0.0425 ± 0.0044       0.0005 ± 6.02E-05 8.94E-05 ± 1.14E-05 
 
       # 0 
Bandicoot B21 0.0049 ± 0.0006      4.87E-05 ± 4.87E-06 
 
2.38E-05 ± 3.48E-06        # 0 
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5.5.2 Penicillin G exposure results in abnormal chlamydial morphology in the 
human and animal C. pneumoniae isolates 
The morphological appearance of the inclusions during the penicillin treatment was 
analysed using confocal microscopy at 72 h PI for each of the treatment conditions 
(Fig.5.3). Persistent inclusions are smaller and often contain larger cells within the 
inclusion, or less staining within the inclusion, when examined by confocal 
microscopy. The control inclusions appear as expected, with the animal isolates 
having much larger inclusions than the human isolates, and all inclusions under the 
control conditions having abundant LPS staining inside the inclusion, consistent with 
what we have previously reported for these isolates (Chapter 4) (Fig.5.3). The 
inclusion size and appearance markedly changed for the 50 U ml-1 penicillin 
conditions for all of the isolates. Substantially reduced inclusion sizes and much less 
intensity of LPS staining inside the inclusion were observed; suggesting altered 
cellular morphology within the cells. In order to quantify the differences in inclusion 
size and also to measure if the reduced infectious progeny observed in Fig 1 reflects 
reduced inclusion size or may also be impacted by ability to maintain the inclusion 
after penicillin was added at 4 h PI (infectivity), the inclusion size and percent 
infectivity was quantified from confocal images. The inclusion sizes (Table 5.2) 
showed a marked decrease in size at 50 U ml-1 penicillin compared to the control for 
all isolates (p <0.001) that did not further reduce in size in a dose dependent manner 
for any of the isolates.  
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Figure 5.3 Penicillin exposure alters chlamydial morphology in both human and animal C. 
pneumoniae isolates.  
BEAS-2B cells were plated on glass coverslips and were infected at an MOI of 0.1 with C. 
pneumoniae isolates. Chlamydial inclusions are shown in green and host cells are shown red. (A-E) 
Representative confocal images of human AR39 C. pneumoniae cultures from control, 50, 100, 200 
and 500 U ml-1 penicillin at 72 h PI. (F-J) Representative confocal images of human A03 C. 
pneumoniae cultures from control, 50, 100, 200 and 500 U ml-1 penicillin at 72 h PI. (K-O) 
Representative confocal images of animal LPCoLN C. pneumoniae cultures from control, 50, 100, 
200 and 500 U ml-1 penicillin at 72 h PI. (P-T) Representative confocal images of animal B21 C. 
pneumoniae cultures from control, 50, 100, 200 and 500 U ml-1 penicillin at 72 h PI. The scale bar in 
the bottom right of each image represents 10μm. 
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Table 5.2. Inclusion sizes for human and animal C. pneumoniae strains during penicillin G exposure at 72 h PI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion sizes from each condition are represented as mean ± SD and are measured from independent coverslips n=20. 
Statistics was conducted using Student’s two-tailed t-test compared to the control culture (No penicillin treatment) (# represents ***p < 0.001).
 No PEN 50 PEN 100 PEN 200 PEN 500 PEN 
Human AR39 9.19 ± 1.74 2.91 ± 0.94# 2.88 ± 1.00# 2.90 ± 0.94# 2.43 ± 0.34# 
Human AO3 7.99 ± 1.39 2.86 ± 0.98# 2.85 ± 0.99# 2.68 ± 0.68# 2.49 ± 0.64# 
Koala LPCoLN 21.21 ± 4.58 6.21 ± 1.39# 6.08 ± 1.16# 6.12 ± 1.03# 6.23 ± 1.02# 
Bandicoot B21 24.86 ± 5.00 5.97 ± 1.13# 5.90 ± 1.21# 5.73 ± 1.20# 5.94 ± 1.18# 
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5.5.3 Reduction in the percentage of cells infected by human and animal C. 
pneumoniae isolates during penicillin G exposure 
In order to identify the loss of infectious progeny production in Fig.5.2, the 
percentage of cells infected were determined during penicillin G treatment (72 h PI 
time point used for analysis)  (Table 5.3). Except for the human AO3 isolate, all the 
three C. pneumoniae isolates showed a dose dependent decrease in the percentage of 
cells infected during penicillin treatment. The percentage of cells infected by AR39, 
LPCoLN and B21 isolates (Table 5.3) corresponded with the observed reduction in 
the infectious progeny during penicillin G treatment (Fig.5.2 A, C and D). The 
percentage of cells infected for the human AO3 control cultures (without penicillin G 
treatment) showed the lowest mean (4.21% (± 1.76 SD) however, during penicillin G 
treatment the human AO3 isolate showed minor reductions in the percentage of cells 
infected.
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Table 5.3. The percentage of cell infected for each strain C. pneumoniae strain during penicillin G exposure at 72h PI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage of cell infected from each condition are represented as mean ± SD and are measured from independent coverslips n=20.  
Statistics was conducted using Student’s two-tailed t-test compared to the control culture (No penicillin treatment) (# represents ***p < 0.001).  
 No PEN 50 PEN 100 PEN 200 PEN 500 PEN 
Human AR39 6.37 ± 1.77 4.21 ± 1.76# 3.75 ± 1.86# 1.85 ± 1.00# 0.79 ± 0.32# 
Human AO3 4.21 ± 1.76 2.27 ± 1.10# 2.12 ± 0.94# 2.30 ± 1.32# 1.01 ± 0.67# 
Koala LPCoLN 8.64 ± 2.61 6.90 ± 2.23 4.38 ± 2.20# 2.83 ± 1.25# 0.83 ± 0.31# 
Bandicoot B21 7.45 ± 2.84 4.38 ± 2.20# 2.83 ± 1.25# 2.30 ± 1.32# 0.80 ± 0.31# 
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5.5.4 The animal C. pneumoniae isolates are not able to be rescued from the 
penicillin induced lack of infectious progeny production 
The key feature of chlamydial persistence is that the loss of infectious forms can be 
rescued by removal of the persistence inducing agent. Therefore, we measured the 
ability to restore the infectivity to these cultures by removal of penicillin to 
determine if the growth characteristics observed here are consistent with persistence. 
Cultures were conducted with penicillin treatment at 4 h PI, removal of the penicillin 
at 72 h PI, and continued culture until 144 h PI, to allow recovery from persistence 
and development of infectious progeny. For the control cultures, the penicillin was 
not removed. The inclusion forming units were measured from these cultures 
harvested at 144 h PI. The human isolates A03 and AR39 both showed considerable 
increases in infectious progeny recovery when 50 U ml-1 and 100 U ml-1 penicillin 
treated cultures were rescued. AR39 infectious yield increased by 2 log relative to 
the control (113 FC relative to non-rescue control) when 50 U ml-1 culture was 
rescued for 72 h, and the 100 U ml-1 culture, which had a complete loss of viability 
without removal of penicillin, had a very remarkable 3 log of infectious progeny 
recovery (Fig.5.4.). The human strain A03 demonstrated even more marked recovery 
of infectious progeny, with ~2.5 log higher infectious yield with 50 U ml-1 culture 
was rescued (208 FC; 203.4 IFU ml-1 compared to rescue yield of 16253.7 IFU ml-1); 
~1.5 log higher infectious yield when the 100 U ml-1 culture was rescued (29 FC; 
712 IFU ml-1 compared to rescue yield of 20649 IFU ml-1) (Fig.5.4.). 3 log of 
infectious inclusion forming units were detected after the 200 U ml-1 penicillin 
treated A03 culture was rescued (from no detectable growth in the 200 U ml-1  
treatment), the only isolate that demonstrated any recoverability from this 
concentration of penicillin. 
In stark contrast, both the animal isolates showed minimal (if any) ability to recover 
from penicillin treatment. There appeared to be minor recovery in infectious progeny 
for the animal LPCoLN after rescue from both 50 and 100 U ml-1 cultures, relative to 
non-rescued control (1.75 and 1.25 FC respectively or; 34889 IFU ml-1 rescued from 
50 U ml-1 compared to 19937 IFU ml-1 and 24921 IFU ml-1 rescued from 100 U ml-1 
compared to 19937 IFU ml-1) (Fig.5.4C.). Similarly for the B21 animal isolate, some 
relatively minor recovery of infectious progeny was observed from both the 50 and 
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100 U ml-1 penicillin rescued cultures (Fig.5.4D.). Specifically, a 2.6 FC relative to 
the non-rescued control was detected for the 50 U ml-1 rescued cultures (22905 IFU 
ml-1 rescued compared to 11392 IFU ml-1 from 50 U ml-1 continued treatment), and 
7.2 FC relative to the control was observed for the 100 U ml-1 rescued culture. These 
relatively minor recoveries in infectious progeny are considerably distinct compared 
to both human isolates, even though there were differences between all four isolates 
for the initial infectious progeny loss due to penicillin treatment. However, there was 
a significant difference between the human isolates, with the A03 human heart 
isolate demonstrating the strongest ability to recover infectious progeny from 
penicillin treatment. Recovery was to higher yields at lower doses and detected at a 
higher dose (200 U ml-1) that AR39 was not able to demonstrate any detectable 
recovery at all.  
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Figure 5.4 Inclusion forming units at 144 h PI for each isolate that has been ‘rescued’ (i.e. 
penicillin removed at 72 h PI) and controls that were not rescued. 
The figure shows the infectious yield (IFU ml-1) of cultures with penicillin G treatment until 144 h PI 
or cultures where penicillin G was removed at 72 h PI and were replenished with penicillin free 
medium until 144hPI (i.e. 72 h post penicillin G removal). The legends are indicated at the right of the 
figure and # indicates that no infectious progeny was detected. (A) The infectious yield (IFU ml-1) of 
human AR39 C. pneumoniae isolate from cultures harvested at 144 h PI. (B) The infectious yield (IFU 
ml-1) of human AO3 C. pneumoniae isolate from cultures harvested at 144 h PI. (C) The infectious 
yield (IFU ml-1) of animal LPCoLN C. pneumoniae isolate from cultures harvested at 144 h PI. (D) 
The infectious yield (IFU ml-1) of animal B21 C. pneumoniae isolate from cultures harvested at 144 h 
PI. 
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Table 5.4 Fold change data of inclusion forming units compared to the controls for each isolate 72 h after treatment for 72 hrs and then the removal of penicillin G 
treatment at 144 h PI (an additional 72 h after penicillin G was removed) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            # 0 indicates no fold change was analysed due the absence of infectious progeny in these cultures. Data are mean ± SEM.
      50 PEN           100 PEN 200 PEN 500 PEN 
Human AR39 0.0062 ± 0.0008       0.0004 ± 0.00003            # 0        # 0 
Human AO3 0.0912 ± 0.0135       0.0083 ± 0.0013  0.0003 ± 0.00008        # 0 
Koala LPCoLN 0.0001 ± 0.00001       0.00008 ± 0.0000          # 0        # 0 
Bandicoot B21 0.0001 ± 0.00001      0.00004 ± 0.0000 
 
         # 0        # 0 
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5.6 DISCUSSION 
The data presented in this chapter demonstrates that the human C. pneumoniae 
strains are well adapted to survive penicillin G induced stress responses compared to 
the animal C. pneumoniae strains. Penicillin G treatment reduced the infectious 
progeny production in both human and animal C. pneumoniae isolates. The human 
isolates, AR39 and AO3 showed complete loss of infectious progeny at higher 
concentrations of penicillin G (200 or 500 U ml-1) and marked reductions in the 
infectious progeny production were observed at intermediate concentrations of 
penicillin G (50 or 100 U ml-1). At 50 U ml-1 penicillin G, the human respiratory 
(AR39) isolate demonstrated a reduction in the infectious progeny from 104 (72 h PI, 
fig 5.2) to 102 (144 h PI, fig 5.4). By comparison, the production of infectious 
progeny for the human aortic (AO3) isolate remained the same at both time points 
(72 and 144 h PI) tested. These results clearly demonstrate that the human isolates do 
differ in their sensitivity to penicillin exposure, which is in contrast to some of the 
earlier observations which suggest that the C. pneumoniae isolates (respiratory and 
aortic isolates) are homogenous and do not differ in their antibiotic susceptibility 
patterns (Gieffers et al., 1998). Consistent with previous literature, the reduced 
infectious progeny production in human isolates after penicillin G treatment was 
accompanied by the presence of persistent chlamydial inclusions (Wolf et al., 
2000b). Exposure to penicillin G induced the development of characteristic aberrant 
bodies within the inclusions and demonstrated an appearance consistent with many 
previous studies (Goellner et al., 2006; Huston et al., 2008; Leonhardt et al., 2007; 
Skilton et al., 2009). Both the human isolates demonstrated normal granular 
appearance in control cultures and showed large spherical structures in penicillin 
exposed cultures (Fig 5.3). In addition to the abnormal inclusion morphology, 
penicillin G exposure also resulted in the reduction of the inclusion size and the 
percentage of infected cells in the human isolates. The animal C. pneumoniae 
isolates (B21 and LPCoLN) also demonstrated some sensitivity to penicillin G 
exposure and showed a dose dependent decrease in the production infectious 
progeny. Interestingly, penicillin G exposure resulted in abnormal morphology in 
animal isolates and showed marked reductions in inclusion size and percentage of 
infected cells. Since this is the first reported evidence of penicillin induced 
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morphological changes in animal isolates, these observations cannot be compared 
with existing literature. Although, morphological analysis is subjective, one of the 
main features of classical chlamydial persistence is the formation of aberrant bodies 
in the presence of the inducer (Hogan et al., 2004b; Schoborg, 2011). Even though 
the animal isolates appear to exhibit abnormal inclusion morphology, the reduced 
recoverability of these isolates upon removal of penicillin G stressor, suggests that 
they are not entering into persistence. Ultrastructural analysis is required to further 
characterize the abnormal inclusion morphology demonstrated by these animal 
isolates.  
Perhaps the most critical finding of this work however, was the fact that the human 
C. pneumoniae isolates are better adapted in recovering from persistence after the 
removal penicillin G treatment, compared to the animal isolates. The fold change 
analysis of recovered infectious progeny after the removal of penicillin G treatment 
(Table 5.4) indicates the failure of the animal isolates to restore the lost infectious 
progeny. However, the significant recovery of infectious progeny following the 
withdrawal of the stressor clearly supports our conclusion that the human isolates 
were viable but non-cultivable following penicillin G treatment (Table 5.4). While 
the high concentrations of penicillin G were lethal (infectious progeny could not be 
subsequently recovered), intermediate concentrations caused the human isolates to 
enter persistence. There have been some observations suggesting the inefficiency in 
the recovery of the persistent human C. pneumoniae (AR39) as compared to the 
persistent C. trachomatis (serovar L2) upon the withdrawal of ampicillin (Wolf et al., 
2000b). However, the differences in the recovery of infectious progeny in human 
AR39 isolate between our study and previous observations could be related to the use 
of two different types of β lactams in these experiments.  Furthermore, a recent study 
also reported differences in the recovery of infectious progeny in C. trachomatis 
serovar E after a range of different β lactams were used in these cultures (Kintner et 
al., 2014).  
The human aortic isolate (AO3) demonstrated an increased ability to survive and 
revert back from penicillin G exposure, as compared to the respiratory isolate. The 
human AR39 and AO3 isolates showed no detectable infectious progeny in the 
presence of 200 U ml-1 of penicillin G, however upon the removal of stressor, only 
the human AO3 isolate was able to substantially restore (2.5 logs) the infectious 
progeny. In direct comparison, the animal isolates were not able to revert back to 
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form infectious progeny after the removal of penicillin G. Both B21 and LPCoLN 
isolates were unable to recover the lost infectious progeny even 72 h after the 
removal of penicillin G from the cultures. Therefore, based on these observations we 
speculate that the animal isolates are not well adapted to survive or undergo 
persistence to withstand penicillin G stressor. Also, to rule out the possibility that the 
animal isolates might take longer than the human isolates to recover the lost 
infectious progeny, we incubated the cultures for longer than 72 h (until 216 h PI) 
after the removal of penicillin, however these attempts were unsuccessful due to the 
death of the host cells. These observations are consistent with our previous result 
(chapter 4) examining the IFN-γ induced persistence model (tryptophan depletion) 
and recovery for these same isolates. During the IFN-γ model, the animal isolates 
also had notable reductions in the precent of infected cells (inclusion numbers 
declined) (likely indicating death) than the human isolates, and also were much less 
able to recover infectious progeny compared to the human isolates. In spite of these 
remarkable differences in growth and persistence the genome sequences between the 
C. pneumoniae strains are relatively highly conserved. However, upon analysis of the 
published genome sequences there are non-synonymous SNPs between human and 
animal isolates (LPCoLN and AR39) in the penicillin binding proteins and related 
proteins that might be relevant to these findings (Mitchell et al., 2010a; Mitchell et 
al., 2010c; Read et al., 2000a). PBP3 has three non-synonymous SNPs, one of which 
introduces a premature stop codon making the protein five residues shorter in 
LPCoLN (Mitchell et al., 2010a; Mitchell et al., 2010c; Read et al., 2000a). PBP2 
has seven non-synonymous SNPs in LPCoLN compared to AR39. MreC has one 
non-synonymous SNP in LPCoLN compared to the AR39 sequence (Mitchell et al., 
2010a; Mitchell et al., 2010c; Read et al., 2000a). However, in all instances the SNPs 
are not in core protein motifs and are not predicted to alter the secondary structure, 
so there are no candidates that could be unequivocally used to explain the data we 
present here. 
Although the current literature shows that penicillin G induces persistence in 
different chlamydial strains (Johnson and Hobson, 1977; Peters et al., 2005; Wolf et 
al., 2000b). There have been some conflicting observations that the penicillin G 
exposure of chlamydia-infected cells does not induce persistence and instead results 
in bacterial death (Dumoux et al., 2013). The authors of this study speculated, that 
the previous reports claiming to demonstrate chlamydial persistence after penicillin 
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G exposure have either added the penicillin G outside the RB stage or have incubated 
the penicillin G for too short a duration, or have used cycloheximide in their cell 
culture experiments and this could inactivate host defenses against chlamydial 
infections and allow the recovery of infectious progeny after the removal of 
penicillin G. However, in our cell culture model the penicillin G was added during 
the C. pneumoniae RB replication stage (4 h PI) and the infected cultures were 
incubated with penicillin G until 72 h PI. The efficient recovery of infectious 
progeny by the human isolates after the removal of penicillin treatment in our study 
was not performed in the presence of cycloheximide and therefore the marked 
recovery demonstrated by the human isolates was not associated with the use of 
cycloheximide. Similarly, the failure of the animal isolates to induce persistence after 
penicillin G exposure was also not due to these experimental discrepancies.  
The findings of this study demonstrate that the human C. pneumoniae isolates are 
better adapted to survive penicillin G exposure. While high concentrations of 
penicillin G are lethal, intermediate concentrations cause the human isolates to enter 
persistence and subsequently, they can resume the normal developmental cycle 
producing infectious EBs upon the removal of penicillin. The AO3 cardiovascular 
isolate demonstrated an enhanced ability to survive penicillin G treatment and to 
recover infectious EBs upon the removal of penicillin G. In stark comparison, the 
animal isolates were not able to recover after the penicillin G was removed. In 
conclusion, these observations are consistent with our previous results, where we 
showed that the human isolates were highly adapted in surviving IFN-γ persistence 
and were extremely efficient in complete restoration of infectivity as compared to the 
animal isolates (chapter 4). The results of these two studies strongly suggest that the 
human C. pneumoniae isolates have acquired unique adaptations to survive under 
unfavourable physiological conditions. Thus, the findings of this study support the 
possibility of entering into persistence as positive survival mechanism by human C. 
pneumoniae isolates. 
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The work presented in this thesis has made important new contributions to our understanding 
of C. pneumoniae specific adaptations to stress responses and has provided new perspectives 
on the survival of this successful pathogen. This study has used two well-established 
microbial stressors (IFN-γ or penicillin exposure) and has identified major differences in 
stress responses between human and animal C. pneumoniae isolates. The major finding to 
emerge from this research was the adaptability of human C. pneumoniae isolates to alter their 
developmental cycle and enter a viable but non cultivable state in an attempt to resist IFN-γ 
or penicillin-G induced stressors. The human respiratory and cardiovascular isolates both 
demonstrated complete loss of infectious progeny production after IFN-γ and penicillin-G 
treatments. The reductions in infectious progeny production also corresponded to the 
decreased number and size of the chlamydial inclusions present in these cultures. The human 
isolates also showed efficient recovery of infectious progeny production after the removal of 
the stressors. Consistent with our findings, previous studies have reported C. pneumoniae 
human isolates TW183 (a respiratory isolate)(Byrne et al., 2001), CV-6 (cardiovascular 
isolate) (Bellmann-Weiler et al., 2010), BAL-36 and BAL-37 (broncheolar lavage isolates) 
(Mehta et al., 1998; Pantoja et al., 2000a) to be sensitive to IFN-γ mediated tryptophan 
depletion. There appears to be IFN-γ dose dependent differences between the sensitivity of 
the human C. pneumoniae isolates, however this could possibly be related to the variations 
between these studies in terms of the time of IFN-γ addition to the cultures and the batch 
variations of IFN-γ activity between suppliers. Furthermore, similar sensitivity to penicillin-G 
has also been demonstrated in human C. pneumoniae respiratory isolates (TW183, CWL-029, 
MUL-1, Kajaani 7 and AR39) and the cardiovascular isolates (CV-1 and CV-3 to CV-6) in 
epithelial cells (Gieffers et al., 1998; Wolf et al., 2000a). These findings clearly suggest that 
the human C. pneumoniae isolates have exquisite stress responses to modulate their survival 
under unfavourable conditions. 
 
The significant findings to emerge from this study is also the increased ability of the human 
cardiovascular isolate A03, to both enter persistence and then to subsequently recover from 
persistence, compared to the human respiratory isolate. During IFN-γ or penicillin-G induced 
stressors, the cardiovascular isolate showed much greater reduction in infectious progeny 
production. Interestingly, after the removal of the stressor, the cardiovascular isolate showed 
highly efficient recovery of infectious progeny compared to the human respiratory isolate. 
The ability of the cardiovascular isolate to transition into a chronic persistent stage, perhaps 
enables this isolate to hide inside circulating monocytes which are believed to be the vehicle 
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for systemic spread of C. pneumoniae infection from the primary respiratory site to the 
vascular site (Yang et al., 1995). The treatment of chronic persistent human C. pneumoniae 
infections has been suggested to be refractory to antibiotics within cultured blood monocytes 
in vitro (Gieffers et al., 2001). The PCR data from patients with C. pneumoniae infection 
suggest that the organism can persist for many years, even after antibiotic treatment 
(Hammerschlag et al., 1992).  For many antibiotics, including penicillin, the bacterial growth 
rate governs the ability of antibiotic efficacy; therefore the reduced growth rate of the 
persistent human C. pneumoniae infections could explain the reduction in the antibiotic 
susceptibility patterns during chronic infections (Cohen et al., 2013; Hogan et al., 2004b). A 
number of in vitro studies have suggested human C. pneumoniae specific mechanisms, which 
might explain the different biological behaviour of this pathogen compared to other 
chlamydial species. In an in vitro comparative study, Marangoni et al. (2014) demonstrated 
that the human C. pneumoniae (FB/96) respiratory isolate infected blood monocytes were 
able to delay the production of reactive oxygen species and cytokines, consequently delaying 
the C. pneumoniae killing activity by infected monocytes, when compared to C. trachomatis 
(L2 serovar) (Marangoni et al., 2014). At the early stages of respiratory infections in vivo this 
delay in the C. pneumoniae infected monocyte response could support the ability of C. 
pneumoniae to spread to other permissive cells (endothelial cells). Furthermore, Mueller and 
colleagues showed that C. pneumoniae AR39 (but not C.trachomatis) disrupts the endothelial 
nitric oxide synthase enzyme trafficking in primary human aortic endothelial cells, resulting 
in the impairment of NO production in these aortic cells (Mueller and Wolf, 2014). The 
inhibition of NO production by C. pneumoniae infected endothelial cells leads to abnormal 
endothelial function, one of the factors associated with the development of cardiovascular 
disease. The authors showed that the interception of endothelial nitric oxide synthase enzyme 
to the plasma membrane is caused by the co-localization of enzyme with C. pneumoniae 
inclusions. There have also been some observations which have correlated the genetic 
differences between human C. pneumoniae isolates to tissue tropism. The genotypic 
differences in tyrosine permease (tyrP) copy numbers and coding sequences has been linked 
to tissue tropism in human C. pneumoniae isolates (Gieffers et al., 2003b) A single copy of 
tyrP gene in human C. pneumoniae has been associated with cardiovascular tropism whereas 
multiple copies of this gene have been putatively linked to respiratory and brain isolates 
(Chacko et al., 2015; Gieffers et al., 2003b). While this is an interesting observation, the 
biochemical activity of chlamydial tyrP protein is still unknown. 
 
  
Chapter 6: General Discussion 151 
The current study has also shown the reduced sensitivity and recoverability of the animal C. 
pneumoniae isolates to IFN-γ or penicillin-G induced stressors, resulting in the failure of 
animal isolates to adapt to these stressors as effectively as the human isolates. Taken together, 
these results suggest that the animal isolates are not able to readily adapt to IFN-γ or 
penicillin-G induced stressors by the induction of a persistence mode of growth that can be 
subsequently rescued. The failure of the animal isolates to restore their infectious progeny 
after the removal of both stressors tested in this study, suggests the possibility of death or 
failure to infect in the presence of these stressors. This study has demonstrated that human C. 
pneumoniae isolates uses IFN-γ or penicillin-G induced stressors to transition to a chronic 
persistent state as a survival mechanism to resist unfavourable growth conditions, whereas 
the animal C. pneumoniae isolates prefer to grow as acute infections, ensuring their survival 
by completing their development cycle with the production of large numbers of infectious 
progeny to infect other cells. The proposition that animal isolates are more likely to cause 
acute infection is well supported in the literature, as evidenced by the clinical presentation of 
the hosts from which the isolates were collected. The koala C. pneumoniae LPCoLN isolate 
used in this study was initially isolated from an outbreak of acute respiratory disease which 
affected around 70% of the captive population of koalas at Lone Pine Koala Sanctuary, 
Australia (Wardrop et al., 1999). Subsequent studies identified cases of C. pneumoniae from 
a wide range of animal hosts (western barred bandicoot, puff adder, chameleon, iguanas, 
green turtle and blue mountain tree frogs) where the majority of the animals presented with 
acute clinical symptoms. In vitro studies also appear to support the acute clinical presentation 
of animal C. pneumoniae isolates. The acute nature of animal C. pneumoniae infection is 
particularly highlighted by firstly the propensity of the koala C. pneumoniae LPCoLN isolate 
to infect both human and koala derived monocytes in vitro, exhibiting increased progeny 
production in comparison to the human C. pneumoniae respiratory isolates (TW183 and 
WA97001) which showed restricted growth with lower progeny production in these 
monocytes (Coles et al., 2001). Secondly, by the in vitro observations demonstrating the 
increased progeny production by animal C. pneumoniae isolates (Koala LPCoLN and 
Bandicoot B21) compared to the human C. pneumoniae isolates (AR39 and AO3) in human 
epithelial cells. In contrast, it appears that human C. pneumoniae presents as more chronic 
disease presentation, with human C. pneumoniae more able to infect or even propagate in 
some host immune cells, which may facilitate systemic dissemination (Abdul-Sater et al., 
2010; Azenabor and Chaudhry, 2003; Beagley et al., 2009), and evidence or isolation of 
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human C. pneumoniae from a range of tissue chronic disease sites has helped build the 
possible association with chronic disease (Bauriedel et al., 1999; Bauriedel et al., 2000). 
The persistent phase of growth is induced by a range of conditions, including; immune stress 
(specifically IFN-γ mediated depletion of tryptophan), antibiotics, co-infections with viruses, 
and iron depletion (reviewed, (Schoborg, 2011; Wyrick, 2010b)). Whilst many of these 
models have been conducted in C. trachomatis, persistence may well have been the 
underlying mechanism that leads to chronic disease in humans in the case of C. pneumoniae. 
There are already distinctions between the two species (C. pneumoniae and C. trachomatis), 
with C. pneumoniae more able to infect or even propagate in some host immune cells, which 
may facilitate systemic dissemination (Abdul-Sater et al., 2010; Azenabor and Chaudhry, 
2003; Beagley et al., 2009). Accordingly, it has been established that IFN-γ induction of IDO 
expression can induce persistence of C. pneumoniae in HEp-2 cells (Mehta et al., 1998), 
aortic smooth muscle cells (Pantoja et al., 2000b, 2001), and endothelial cells (Bellmann-
Weiler et al., 2010), but not in lymphocytes (Ishida et al., 2013). Additionally, it has been 
established that penicillin and iron limitation, can also induce persistence in HeLa cells (Klos 
et al., 2009b). Gene expression array data supports that the C. pneumoniae persistence 
models involve continued DNA replication that is uncoupled from cytokinesis (Byrne et al., 
2001). In addition to these in vitro persistence models, C. pneumoniae has been both 
observed and cultured from systemic chronic disease locations, including aortic or plaque 
tissue and brain tissue (Balin et al., 1998; Bauriedel et al., 1999; Bauriedel et al., 2000; 
Ramirez, 1996a). Hence, C. pneumoniae persistence appears to be a potential factor in the 
chronic diseases associated with this organism.  
 
The findings of our study provide further evidence, that the human C. pneumoniae isolates 
have specific adaptations to withstand IFN-γ or penicillin-G induced stressors, which clearly 
implies that the human C. pneumoniae assures its survival by diverting its infectious cycle 
across to the persistent stage, which is a well-defined separate phase of infection pathogenesis 
governed by specific bacterial adaptations rather than non-specific sequelae of the infection. 
Perhaps the ability of human C. pneumoniae to establish asymptomatic persistent infections 
aids in the spread of disease and could explain why as much as 80% of the human population 
are infected with C. pneumoniae (reviewed in Watson and Alp, 2008). 
Furthermore, the two major mechanisms employed by other chlamydial species to survive 
host mediated tryptophan starvation are primarily by differentiating to a viable but non-
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cultivable form like human C. pneumoniae and secondly by maintaining different levels of 
conservation of tryptophan biosynthesis operon (reviewed Hogan et al., 2004b). It appears 
that some strains of Chlamydia can synthesise or at least recover tryptophan, although the 
presence of a functional tryptophan synthase and an appropriate source of key intermediates 
in tryptophan biosynthesis govern this ability. The human urogenital C. trachomatis strains 
encode a functional tryptophan synthase enzyme, which can utilize indole as substrate for 
tryptophan synthesis (Fehlner-Gardiner et al., 2002b). Genital tract microflora, secrete indole 
suggesting that C. trachomatis genital strains have developed a mechanism to overcome IFN-
γ mediated tryptophan depletion using environmental niche to synthesis tryptophan (Caldwell 
et al., 2003). In contrast, C. trachomatis strains isolated from ocular and synovial tissue lack 
functional tryptophan synthase and appear to be much more sensitive to the effects of 
tryptophan depletion than the urogenital strains (Morrison, 2000). Another chlamydial 
species, C. caviae encode the most complete tryptophan biosynthesis operon, resulting in 
complete resistance to tryptophan starvation (Read et al., 2003; Wood et al., 2004b). Even 
though the intracellular anti-chlamydial effectors in murine cells are driven by IDO 
independent p47GTPase pathway, C. muridarum has been shown to express a unique species-
specific functional cytotoxin, which could possibly be involved in inactivating host cellular 
p47GTPase (Nelson et al., 2005). This cytotoxin, or at least the comparative resistance to 
IFN-γ, is likely a rodent-specific adaption for this Chlamydia because rodents (unlike many 
other animals) do not induce the IDO1-kynurenine pathway to the same level or in as many 
tissue locations as the immune activation of IDO1 that has been reported in non-human 
primates, gerbils, and guinea pigs (reviewed in Murakami and Saito, 2013a). In addition to 
this there is evidence that IFN-γ activates IDO1 tryptophan depletion in sheep cells (Brown et 
al., 2001). We have recently identified that the IFN-γ gene is present in the koala 
transcriptome and that IFN-γ gene expression was induced when koala peripheral blood 
mononuclear cells were incubated with Chlamydia pecorum (Mathew et al., 2013b). IDO1 
and IDO2 are also present in the koala transcriptome (Hobbs et al., 2014). Thus, tryptophan 
depletion in response to immune activation is likely a common host defence mechanism; and 
yet, in spite of this likely conservation, we have clearly identified human and animal strain 
differences in susceptibility to this mechanism. 
 
Apart from having adaptations to withstand host immune mediated starvation, chlamydiae 
have also evolved sophisticated mechanisms to maintain favourable habitat for its 
intracellular growth while avoiding harm to the infected host cell (reviewed in Cocchiaro and 
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Valdivia, 2009). Chlamydia appears to interfere with NF-κB mediated host inflammatory 
pathways, which regulates the key aspects of host innate and adaptive immunity (Hayden et 
al., 2006). C. trachomatis tail-specific protease (Ct441) has been demonstrated to cleave one 
of the heterodimeric subunit (NF-κB p65) required for the transcriptional activation of NF-κB 
(Lad et al., 2007). In addition to this, C. trachomatis encodes two proteins ChlaDub1 and 
ChlaDub2 which inhibit the degradation of IκBα resulting in the blockage of NF-κB 
activation (Le Negrate et al., 2008; Misaghi et al., 2006). Although, C. pneumoniae lacks 
these effector proteins (ChlaDub1 and ChlaDub2), IL-17 induced NF-κB activation (a key 
host immune response to microbial infection of lung) is inhibited by C. pneumoniae specific 
inclusion membrane protein CP0236. Interaction of C. pneumoniae specific inclusion 
membrane protein CP0236 with NF-κB activator 1 (Act1) alters the recruitment of Act1 to 
one of the heteromeric receptor complex (IL-17RA), inhibiting IL-17 activation which in turn 
blocks NF-κB activation (Wolf et al., 2009b). Furthermore, Chlamydia blocks host cell 
apoptosis by degrading selected pro-apoptotic Bcl-2 family proteins, which regulate the 
release of mitochondrial cytochrome c (a key step in apoptotic signalling pathway) (Kawana 
et al., 2007; Ying et al., 2005). Thus, chlamydial species have unique evasion strategies to 
colonize host tissues and cause chronic diseases.  
 
Other intracellular pathogens like Mycobacterium tuberculosis and Legionella pneumophila, 
have also acquired diverse adaptations to overcome different stressors. M. tuberculosis has an 
exceptional ability to persist for many years inside the nutrient starved environment of 
caseous lung granulomas, indicating that the pathogen has substantial ability to withstand 
host immune mediated starvation and damage. M. tuberculosis is able to withstand not only 
IFN-γ mediated tryptophan depletion, but also other essential amino acid starvation, by 
constitutively expressing the complete amino acid biosynthesis genes (reviewed Zhang and 
Rubin, 2013). In addition to these adaptations, the long term survival of non-replicating M. 
tuberculosis is associated with the induction of stringent responses which results in the broad 
reprogramming of bacterial transcription. These stringent responses are initiated by the 
enzymatic action of RelMtb which synthesises and hydrolyses hyperphosphorylated guanine 
nucleotides in response to nutritional stress (Dahl et al., 2003; Klinkenberg et al., 2010). 
Accumulation of these signalling molecules (hyperphosphorylated guanine nucleotides) 
results in the coordinated shutdown of specific metabolic pathways ensuring the long-term 
survival of M. tuberculosis to persist in hostile environment (Primm et al., 2000). Unlike 
energy independent M. tuberculosis, which contains the complete biosynthetic machinery for 
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the synthesis of all 20 amino acids, L. pneumophila exploits host machinery to survive host 
mediated amino acid starvation. L. pneumophila secretes a virulence factor called Ankyrin B 
(AnkB), which acts as a platform for the assembly of polyuniquitinated proteins on the 
surface of legionella containing vacuole (Price et al., 2011; reviewed Zhang and Rubin, 
2013). These polyuniquitinated proteins are then degraded by host proteasome; producing 
free amino acids that are transported into legionella containing vacuole by host amino acid 
transporters (Price et al., 2011; Wieland et al., 2005). Therefore, successful intracellular 
human pathogens are evolved with highly efficient adaptations to counteract host-mediated 
stress.  
6.1 CONCLUSION  
This study adds new perspective to C. pneumoniae persistence and demonstrates that the 
ability to enter and recover from adaptation appears to be a human strain specific feature, and 
this appears to have been enhanced/ or further selected for in strains that have the ability to 
disseminate and be associated with chronic disease tissue locations. The findings of this 
research supports our hypothesis that the disease modes associated with animal and human C. 
pneumoniae persistence are directly linked with the fundamental biological traits around 
ability to persist or not in these different strains. 
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 Non-Viable inclusion  
Fig.6.1 Schematic representation of a model showing major stress responses in human and animal C. pneumoniae isolates under stressors 
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The left of the figure shows in vitro differences during acute phase of human and animal C. pneumoniae 
infection in host epithelial cells. Animal C. pneumoniae isolates (Koala LPCoLN or Bandicoot B21) 
demonstrate increased progeny production compared to human respiratory (AR39) and cardiovascular (AO3) 
isolates during acute infection. During immune (IFN-γ mediated tryptophan depletion) and antibiotic (penicillin 
G) induced stressors the human C. pneumoniae isolates converts from an active replicating inclusion to a 
persistent inclusion. In this chronic phase, the human C. pneumoniae becomes refractory to immune and 
antibiotic stressors, allowing the organism to hide in the host cells until the stressor subsides. After the removal 
of stressors (right of the figure) the human C. pneumoniae isolates revert back to an actively replicating 
inclusion (reactivation phase) resulting in the release of infectious progeny ready to re initiate the infection 
cycle. In stark contrast, the animal isolates showed reduced sensitivity and recoverability to IFN-γ or penicillin-
G induced stressors, resulting in the failure of animal isolates to adapt to these stressors. The failure of the 
animal isolates to restore their infectious progeny after the removal of stressors, suggests the possibility of death 
or failure to infect in the presence of these stressors.     
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6.2  FUTURE DIRECTIONS  
The findings presented in this thesis have expanded the knowledge on C. pneumoniae 
specific adaptations and provides the rational for further work in understanding the cellular 
mechanisms behind C. pneumoniae specific adaptations to stress responses. The next logical 
approach would be to perform RNA-Seq analysis (Humphrys et al., 2013) of simultaneous 
transcriptional profiling of both host and C. pneumoniae isolates under tryptophan depletion 
or penicillin-G induced stressors. Understanding the transcriptional profiling of human and 
animal C. pneumoniae isolates will further elucidate the mechanisms responsible for the 
observed differences between these isolates under IFN-γ or penicillin-G induced stress. In 
addition to this the key human C. pneumoniae specific effectors that are associated with the 
transition from acute to chronic infections could be identified by transcriptional profiling 
which could also provide potential targets for therapeutic interventions. The transcriptional 
profiling of the host in the same experiment will help to identify key host cell transcriptional 
changes that are associated with IFN-γ or penicillin-G induced stress and whether C. 
pneumoniae alters any host cell gene transcription during these stressors. 
 
Despite the lack of appropriate animal specific cell lines, our study has clearly identified 
human and animal strain differences in IFN-γ and penicillin G induced persistence models. 
However, the characteristic differences demonstrated by the animal C. pneumoniae isolates in 
this study could be further validated in animal cells lines. Additional experiments required to 
investigate the distinct biological features of human respiratory and cardiovascular isolate 
demonstrated in this study will include, the ability of human patient derived primary C. 
pneumoniae isolates to infect and enter persistent state in human blood monocytes ex vivo. 
The association of C. pneumoniae infection with atherosclerosis and other neurological 
diseases are potentially linked to its ability to enter persistent state in macrophages and 
monocytes which acts as carriers for the systemic dissemination and reduced antibiotic 
susceptibility of this pathogen. These in vitro persistence models are important for 
understanding how persistent Chlamydiae might act in vivo and will help us to develop better 
in vivo models for studying this pathogen. 
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